UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

THE UNITED STATES OF AMERICA,
Plaintiff–Counterclaim Defendant,

v.

GILEAD SCIENCES, INC.
Defendant–Counterclaim Plaintiff,

AND GILEAD SCIENCES IRELAND UC,
Defendant.

Civil No. 1:19-cv-02103-MN

UNITED STATES' MOTION TO STRIKE

JOSEPH H. HUNT
Assistant Attorney General

DAVID C. WEISS
United States Attorney

GARY L. HAUSKEN
Director

WALTER W. BROWN
Senior Litigation Counsel
PHILIP CHARLES STERNHELL
Assistant Director
PATRICK C. HOLVEY
Trial Attorney
Commercial Litigation Branch,
Civil Division, U.S. Department of Justice
Washington, D.C.

LAURA D. HATCHER
SHAMOOR ANIS
Assistant United States Attorneys
Wilmington, Delaware

June 26, 2020

TABLE OF CONTENTS

TABLE OF AUTHORITIES

Cases

Statutes

Rules

Legislative Sources

Secondary Sources

Plaintiff United States of America (Government or United States) submits, pursuant to Federal Rule of Civil Procedure 12(f), this Motion to Strike the equitable defenses raised in the Second Amended Answer and Counterclaims (D.I. 21) of Defendants Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead). The United States moves as follows:

INTRODUCTION AND BACKGROUND

This is an action brought by the Government against Gilead seeking money damages for infringement of U.S. Pat. Nos. 9,044,509; 9,579,333; 9,937,191; and 10,335,423 (collectively, the Patents-in-Suit). The Government filed its Complaint on November 6, 2019. D.I. 1.

Gilead filed its original Answer and Counterclaims on January 23, 2020. D.I. 7. Gilead filed its First Amended Answer and Counterclaims on March 27, 2020. D.I. 13. The Government filed a Motion to Strike Gilead's equitable defenses on May 15. D.I. 16. The Government concurrently filed a Motion to Dismiss for Failure to State a Claim and Lack of Subject Matter Jurisdiction. D.I. 17. In accordance with a stipulation between the parties, D.I. 19, and in response to the Government's motions, Gilead filed its Second Amended Answer and Counterclaims on May 29, 2020. D.I. 21.

The Second Amended Answer added virtually identical language to each affirmative equitable defense previously challenged by the Government. *Id.* (Affirmative Defenses) at ¶¶ 43, 67, 72, 79, and 84. For each Affirmative Defense, Gilead amended its Counterclaims to add the following legal conclusions: (1) that "the Government has waived [any] immunity" because it "has acted in a proprietary capacity, not in a sovereign capacity, by obtaining and asserting patent rights in the same manner and for the same purpose as a private party," (2) that the Government has waived immunity because it "has engaged in affirmative misconduct," and (3) that the

application of immunity would "result in serious injustice to Defendants." *Id.* No new factual allegations were included in the twice-amended Affirmative Defenses.

SUMMARY OF THE ARGUMENT

This case involves four patents that arose out of publicly funded research at the Centers for Disease Control and Prevention (CDC). The inventors conceived of and developed innovative two-drug regimens that could, for the first time, effectively prevent new HIV infections. These novel pre-exposure prophylaxis (PrEP) regimens are now the standard prophylactic protocols for at-risk populations. These regimens, developed by the Government with public funds, are covered by the four Patents-in-Suit.

The Patents-in-Suit are the property of the United States and are held in trust for the American people. Defendants have consistently refused to license the patented technology. Instead, Gilead tried—and failed—to attack the validity of these patents, all the while realizing significant profits from the infringing use of its drugs. Gilead's continued willful infringement of the Government's patents has compelled this suit in the name of the United States in order to protect the public's investment and the public's right to royalty payments from licenses to the patented research.

Because the United States brings this infringement suit in its sovereign capacity to recover funds rightfully owed and unlawfully retained by Gilead, and to enforce and protect the public's interests in protecting intellectual property of the United States, Gilead may not assert the equitable Affirmative Defenses pleaded in its Answer. The Court should, accordingly, strike each of Gilead's equitable Affirmative Defenses (acquiescence and/or estoppel, implied waiver, unclean hands, failure to mitigate, and inequitable conduct).

ARGUMENT

When the United States seeks relief in its courts, the general rule is that it is not subject to any equitable defenses. This rule is excepted only in uniquely compelling situations that are commonly predicated on affirmative, gross governmental misconduct. Gilead does not allege any uniquely compelling conduct by the Government sufficient to justify that exception. Each of Gilead's Affirmative Defenses sounding in equity are thus insufficient as a matter of law and should be struck.

I. THE COURT MAY STRIKE EQUITABLE DEFENSES THAT ARE INSUFFICIENT AS A MATTER OF LAW

"The court may strike from a pleading an insufficient defense . . . ." Fed. R. Civ. P. 12(f). While "disfavored," *Symbol Techs., Inc. v. Aruba Networks, Inc.*, 609 F. Supp. 2d 353, 356 (D. Del. 2009), "a Rule 12(f) motion to dismiss a defense is proper when the defense is insufficient as a matter of law." *Kaiser Aluminum & Chem. Sales, Inc. v. Avondale Shipyards, Inc.*, 677 F.2d 1045, 1057 (5th Cir. 1982). A defense is "insufficient if, as a matter of law, the defense cannot succeed under any circumstance." *FDIC v. Isham*, 782 F. Supp. 524, 530 (D. Colo. 1992). Where a defense must fail, its inclusion prejudices the plaintiff because it increases the duration and expense of trial, *see SEC v. Toomey*, 866 F. Supp. 719, 725 (S.D.N.Y. 1992), and the granting of a motion to strike "avoid[s] the expenditure of time and money that must arise from litigating spurious issues by dispensing with them early in the case." *Operating Eng'rs Local 324 Health Care Plan v. G & W Const. Co.*, 783 F.3d 1045, 1050 (6th Cir. 2015) (quotation omitted). Defenses which would tend to significantly complicate the litigation are particularly vulnerable to a motion to strike. *La. Sulphur Carriers Inc. v. Gulf Res. & Chem. Corp.*, 53 F.R.D. 458, 460 (D. Del. 1971).

Where the United States is the plaintiff, courts routinely grant motions to strike equitable defenses asserted against the government. *See, e.g.*, *United States ex rel. Monahan v. Robert Wood*

Johnson Univ. Hosp., No. 02-5702 (JAG), 2009 U.S. Dist. LEXIS 111347, at *19-21 (D.N.J. Dec. 1, 2009) (striking estoppel and failure to mitigate defenses in False Claims Act (FCA) case); *see also Office of Pers. Mgmt. v. Richmond*, 496 U.S. 414, 419 (1990) ("[E]quitable estoppel will not lie against the Government as it lies against private litigants.").[1] Because Gilead's equitable defenses are categorically "insufficient," they should be stricken.

II. THE GOVERNMENT'S CLAIMS TO REDRESS GILEAD'S UNLAWFUL INFRINGEMENT ARE NOT SUBJECT TO EQUITABLE DEFENSES

The United States enjoys exceptional protections in its courts in pursuing the vindication of public rights, as it is here. *See United States v. Banks*, 115 F.3d 916, 919 (11th Cir. 1997) (differentiating between "claims brought by the federal government in its sovereign capacity" and claims brought "when the government is acting to vindicate private interests, not a sovereign or public interest") (citation omitted). These protections include the exclusion of any equitable affirmative defense as traditionally applied between private parties.[2]

Accordingly, "[t]he case law overwhelmingly supports the Government's position" that "the equitable defenses of waiver, equitable estoppel, laches, unclean hands and *in pari delicto* may not be asserted against the United States when [] it is acting in its sovereign capacity to

[1] *See also United States ex rel. Dye v. ATK Launch Sys.*, No. 1:06-CV-39 TS, 2008 U.S. Dist. LEXIS 85331, at *6–9, *13 (D. Utah Oct. 16, 2008); *United States v. Manhattan-Westchester Med. Servs., P.C.*, No. 06 Civ. 7905 (WHP), 2008 U.S. Dist. LEXIS 5819, at *7–9 (S.D.N.Y. Jan. 28, 2008); *United States v. Cushman & Wakefield, Inc.*, 275 F. Supp. 2d 763, 768–71, 773–74 (N.D. Tex. 2002); *SEC v. Jantzen*, No. A-10-CA-740-JRN, 2011 U.S. Dist. LEXIS 7109, at *5–6 (W.D. Tex. Jan. 25, 2011); *SEC v. KPMG, LLP*, No. 03 Civ. 671 (DLC), 2003 U.S. Dist. LEXIS 14301, at *6–12 (S.D.N.Y. Aug. 20, 2003); *United States v. Dyncorp Int'l LLC*, 282 F. Supp. 3d 51, 57 (D.D.C. 2017). Across all these cited cases, equitable defenses of estoppel, waiver, accord and satisfaction, failure to mitigate, and unclean hands were struck, respectively.

[2] These protections may not apply when, for example, "the Government is suing to enforce a contract between it and a third party, and is thus acting as a private party would." *United States v. Georgia-Pacific Co.*, 421 F.2d 92, 101 (9th Cir. 1970) (emphasis added) (distinguishing enforcement of contract to buy land from enforcement of right in public lands).

exercise public rights to protect the public interest." *United States v. Philip Morris, Inc.*, 300 F. Supp. 2d 61, 65 (D.D.C. 2004) (quotation omitted) (collecting cases). The exclusion of equitable defenses in suits brought by the United States in its sovereign capacity serves "the great public policy of preserving the public rights, revenues, and property from injury and loss, by the negligence of public officers." *United States v. Hoar*, 26 Fed. Cas. 329, 330 (C.C.D. Mass. 1821); *accord United States v. Kirkpatrick*, 22 U.S. (9 Wheat.) 720, 735 (1824).

A. The Government Is Acting In Its Sovereign Capacity

The present action is brought by the sovereign to protect the public's interest. The United States obligated and expended public funds to support the research by government employees that resulted in the Patents-in-Suit. The United States is the owner by assignment of the resulting patent rights and holds title to the patents. It brings this suit directly as the sovereign, as a "suitable and necessary step[] to protect and administer rights to federally owned inventions on behalf of the Federal Government." 35 U.S.C. § 207(a)(3); *see also* 35 U.S.C. § 200 *et seq.* (defining the Government's statutory authority with respect to obtaining, administering and enforcing patents). In this suit, the United States is acting in its sovereign capacity by seeking money damages from Gilead for its willful infringement to protect the Government's and the public's clear interest in federal inventions.[3] Accordingly, ***none*** of Gilead's equitable affirmative defenses are available against the United States.

[3] The Bayh-Dole Act, 35 U.S.C. §§ 200–212, created a common regime for treatment of federal inventions across various agencies to ensure that the public's investment in federal innovation would be protected while promoting the private commercialization of federal inventions. *See* 126 Cong. Rec. 8,739 (1980) (statement of Sen. Dole) ("S. 414 is a determined effort to solve a serious problem that exists, without the Government 'giving away' its patent rights or contributing to the growth of monopolies. . . . [The Act's provisions] guarantee[] that the Government's investment, paid for by the taxpayers of this country, is returned to the Federal coffer . . . ."); *id.* at 8,741 (statement of Sen. Bayh) ("I would like to point out that the bill . . . says that if the Government

Gilead's Second Amended Answer disputes the sovereign capacity of the United States in this action, repeatedly echoing the legal conclusion that "the Government has acted in a proprietary capacity, not in a sovereign capacity, by obtaining and asserting patent rights in the same manner and for the same purpose as a private party (i.e., enforcing a right to exclude Defendants from practicing the claimed inventions unless payment is made in the form of a royalty)." D.I. 21 (Affirmative Defenses) at ¶¶ 43, 67, 72, 79, and 84. Gilead, however, pleads no facts capable of supporting its assertion and the Court should reject it as conclusory and an incorrect statement of law.

Even accepting Gilead's allegation that the Government has "obtain[ed] and assert[ed] patent rights in the same manner and for the same purpose as a private party" as true, Gilead's claims are insufficient as a matter of law to support the conclusion that "the Government has acted in a proprietary capacity, not in a sovereign capacity."

First, there is clear statutory authority establishing that all aspects of the Government's protection of federal intellectual property, that is held in trust for the public's benefit, was invented by federal employees at federal facilities all funded by public monies, and was patented by the Government *via* expenditure of additional monies to protect the public's investment, are sovereign acts. Specifically:

1) The Government is authorized by statute to procure patents to protect federal inventions. 35 U.S.C. § 207(a).

---

feels that a patent they supported is something that they want to develop in the name of the people of the United States, then they have a right to do it.") (emphasis added).

2) The Government is authorized by statute to license federally owned inventions, either royalty-free or for royalties or other consideration, and on such terms and conditions, "as determined appropriate in the public interest." 35 U.S.C. § 207(b).

3) The Government is authorized by statute to directly "undertake all other suitable and necessary steps to protect and administer rights to federally owned inventions on behalf of the Federal Government." 35 U.S.C. § 207(c).

No relevant facts are in dispute here:

1) "Plaintiff is the government of the United States of America (United States or Government) acting on behalf of its Department of Health and Human Services (HHS)." D.I. 1 (Compl.) at ¶ 11.

2) The Patents-in-Suit were all developed as the result of the expenditure of public funds. *See, e.g.*, *id*. at ¶¶ 2, 93, 110, 113, 118.

3) The CDC sought and "[t]he United States Patent and Trademark Office (PTO) granted CDC four patents that protect its innovative regimens and the taxpayers' investment." *Id*. at ¶ 5; *see also id*. at ¶¶ 128, 196.

4) The Government attempted to license the HHS Patents to Gilead, but was unsuccessful. *Id.* at ¶¶ 233–43; *see also* D.I. 21 at 54 (¶ 240) ("Defendants admit that the parties were unable to resolve the dispute and admit they did not enter into a licensing agreement.").

5) Because its licensing attempts were unsuccessful, "[t]he United States of America [brought] this civil action for patent infringement under 35 U.S.C. § 271 *et seq*. against Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) for infringement of" the HHS Patents. D.I. 1 (Compl.) at ¶ 10.

Second, it is long and firmly established that with respect to property of any type, "[t]he United States do not and cannot hold property, as a monarch may, for private or personal purposes," but that "[a]ll the property and revenues of the United States must be held and applied, . . . 'to pay the debts and provide for the common defence and general welfare of the United States.'" *Van Brocklin v. Tennessee*, 117 U.S. 151, 158–59 (1886) (quoting U.S. CONST., art. 1, sec. 8, clause 1). Accordingly, where the United States acts to protect the property it holds, it does so in a sovereign capacity. *Utah Power & L. Co. v. United States*, 243 U.S. 389, 409 (1917); David K. Thompson, *Equitable Estoppel of the Government*, 79 COLUM L. REV. 551, 555 n.39 (1979) ("government actions with respect to federal property are almost invariably regarded as 'sovereign,'") (citation omitted). Unlike situations where the United States may be found to be have "divest[ed] itself of its sovereign character as to that particular transaction," by, for example, "enter[ing] into a contract with an individual or corporation," *Georgia-Pacific*, 421 F.2d at 101, here, the Government "is carrying out its unique governmental functions for the benefit of the whole public" by acting to secure and protect federal intellectual property. *Id.*; 35 U.S.C. §§ 200, 207.

"When the United States becomes entitled to a claim, acting in its governmental capacity, and asserts its claim in that right, it cannot be deemed to have abdicated its governmental authority" such that it becomes subject to equitable defenses such as laches. *United States v. Summerlin*, 310 U.S. 414, 417 (1940); *United States v. Arrow Transp. Co.*, 658 F.2d 392, 394 (5th Cir. 1981) (such defenses "cannot be asserted against the United States in its sovereign capacity to enforce a public right or to protect the public interest"). And this immunity, "[u]nless expressly waived, [] is implied in all federal enactments," *Bd. of Cty. Comm'rs v. United States*, 308 U.S. 343, 351 (1939), including, accordingly, 35 U.S.C. § 207.

Third, Gilead would have this Court establish a rule that the Government never acts in a sovereign capacity in acquiring and defending federal intellectual property rights. Gilead pleads that the Government acts in a proprietary capacity by "enforcing a right to exclude Defendants from practicing the claimed inventions unless payment is made in the form of a royalty." *See, e.g.*, D.I. 21 at 77 (¶ 43). But, a patent is inherently, and primarily, "a grant to the patentee . . . of the right to exclude others from making, using, or selling the invention throughout the United States." 35 U.S.C. § 154. And turning to Gilead's assertion of exclusion "unless payment is made in the form of a royalty," *see, e.g.*, D.I. 21 at 77 (¶ 43), the remedial path the Government may use to protect federal inventions is "by civil action for infringement of his patent." 35 U.S.C. § 281. The Government actions that Gilead references are simply those it is authorized by statute to undertake.

And, indeed, Congress has statutorily announced that the Government should undertake these actions. 35 U.S.C. § 200 *et seq*. is a section of the patent law that applies solely to the sovereign as the rights holder and protector of federal inventions and authorizes the Government to, *inter alia*, "apply for, obtain, and maintain patents or other forms of protection in the United States and in foreign countries on inventions in which the Federal Government owns a right, title, or interest" and, where appropriate, "undertake all other suitable and necessary steps to protect and administer rights to federally owned inventions on behalf of the Federal Government either directly or through contract." 35 U.S.C. § 207(a) (emphasis added). Accordingly, the Government acts in a sovereign capacity when it acquires, administers, and protects federal intellectual property rights.

Further, the Government faces statutory policy considerations that no private entity, like Gilead, considers in administering and protecting the public's rights in federal intellectual property. For example, the Government should "promote the utilization of inventions arising from federally supported research or development," "promote the commercialization and public

availability of inventions made in the United States by United States industry and labor," and "protect the public against nonuse or unreasonable use of inventions." *Id.* The Government is not called by Congress to act in a proprietary capacity, concerned only with extracting all the profits the market can bear at the expense of consumers. To the contrary, the Government is directed to act in favor of the public, first by protecting its investment in federal inventions by securing patents and then by working to widely promote public availability while recovering, if possible, public funds expended for research.

Indeed, considering other instances where the Government acts to protect its property and enforce its rights thereto, equitable remedies have been long held to be "inoperative as against" the sovereign. *Utah Power & L. Co. v. United States*, 230 F. 328, 340 (8th Cir. 1915), *modified*, 242 F. 924 (8th Cir. 1917). For example, in *Utah Power*, the Eighth Circuit rejected such application of equitable remedies where the United States sought to eject the Utah Power & Light Company (acting in the name of the state of Utah) from public lands in Utah. Considering the defense of equitable estoppel, the court noted that while it was true that "with respect to its proprietary interests a sovereign is subject to the principles of equitable estoppel in the same manner and under the same circumstances as a private individual or corporation," *id*. at 339, the "doctrine cannot be so far extended as to validate the unauthorized appropriation of the public lands upon the mere ground of occupation and improvements made." *Id*. at 342. As against the Government "[l]ong acquiescence does not legalize an unwarranted appropriation," "failure to object does not confer any vested right as against the [G]overnment," and "laches is not imputable to the government." *Id.* at 340. Each of these is an equitable defense not to be applied against the Government when it is acting to protect federal property.

The Supreme Court affirmed this rejection in a related appeal of the same underlying district court case. *Utah Power*, 243 U.S. 389. While noting the contention that "the agents in the forestry service and other officers and employees of the government, with knowledge of what the defendants were doing, not only did not object thereto, but impliedly acquiesced therein until after the works were completed and put in operation," the Court nonetheless held that proposition "must fail[, because, as] a general rule, laches or neglect of duty on the part of officers of the government is no defense to a suit by it to enforce a public right or protect a public interest." *Id*. at 409 (citations omitted). "A suit by the United States to enforce and maintain its policy respecting lands which it holds in trust for all the people stands upon a different plane in this and some other respects from the ordinary private suit to regain the title to real property or to remove a cloud from it." *Id.* (emphasis added). The United States brings the present action to enforce and maintain its statutorily announced policy regarding the "domestic and foreign protection of federally owned inventions." 35 U.S.C. § 207.

Finally, unlike private entities, who frequently seek "permanent injunction[s], pursuant to 35 U.S.C. §271(e)(4)(B), restraining and enjoining Defendants . . . from practicing any claim of the patent", *see, e.g.*, Complaint, *Gilead Sci., Inc., et al., v. Watson Labs., Inc., et al.*, C.A. No. 1:15-cv-02350-RMB (D.N.J. April 3, 2015), D.I. 1 at 8 (attached as Exhibit 1), in this action, the Government deliberately has not sought injunctive relief, D.I. 1 (Compl.) at 75, given the potential public health harm.

In short the United States' posture and concerns in this litigation, as sovereign, are far different from that of a private party. As the Government brings this action in the name of the people of the United States, on their behalf, and for their benefit, there should be no dispute this action is brought in the Government's sovereign capacity.

B. Gilead's Claims of Serious Injustice Cannot Save Its Equitable Defenses

As with its pleading of proprietary capacity, Gilead repeatedly claims "serious injustice" resulting from application of the Government's immunity to its affirmative equitable defenses. D.I. 21 (Affirmative Defenses) at ¶¶ 43, 67, 72, 79, and 84.[4] While Gilead asserts different rationales for this "injustice", from deprivation of the benefits of contracts to incurring costs in defending against the Government's complaint, none of these rationales support Gilead's legal position. Simply put, the application of sovereign immunity can seemingly lead to unfair results. *See Stillaguamish Tribe of Indians v. Pilchuck Grp. II, L.L.C.*, No. C10-995RAJ, 2011 U.S. Dist. LEXIS 101222, at *23 (W.D. Wash. Sep. 7, 2011) (citing *Memphis Biofuels, LLC v. Chickasaw Nation Indus., Inc.*, 585 F.3d 917, 922 (6th Cir. 2009)). Even if, however, a result appears to be unfair, that unfairness exists to achieve a greater public good. "A government can only transact its business through its agents, and because its operations are various and its agencies numerous and scattered, even 'the utmost vigilance' would not save the public from the most serious losses" if equitable defenses, such as laches, were permitted. *Cal. ex rel. State Lands Com. v. United States*, 512 F. Supp. 36, 40 (N.D. Cal. 1981) (quoting *U. S. v. Kirkpatrick*, 22 U.S. (9 Wheat.) 720, 735 (1824)). Thus, regardless of Gilead's complaints of potential or perceived unfairness,

[4] Gilead has been clear that "[n]o admission below with respect to GSI should be construed as an admission with respect to GSIUC, nor should any admission below with respect to GSIUC be construed as an admission with respect to GSI." D.I. 21 at 1. Yet Gilead improperly conflates the actions of Gilead Sciences, Inc. (GSI), and Gilead Sciences Ireland UC (GSIUC) in its assertions of serious injustice. For example, GSIUC is not a party to any of the contracts that Gilead asserts "Defendants," including GSIUC, deserve "the benefits of." *Id.* at 77 (¶ 43). GSIUC also was not identified as allegedly "work[ing] with the Government to mitigate the HIV crisis and promote public health," as GSI was. *Id.* at 86 (¶ 72), 88 (¶ 79), 89 (¶ 84). Accordingly, even if the Court were to determine that "serious injustice" affects the availability of the equitable affirmative defenses against the Government, those defenses are not available to GSIUC.

"equitable defenses are not available against a sovereign because rights of the public should not be lost" due to the acts or delays of "the sovereign's agents." *Id.* at 40.

C. Each of Gilead's Equitable Affirmative Defenses Are Insufficient as a Matter of Law

i. Equitable Estoppel, Acquiescence, and Waiver

Gilead pleads the defense of acquiescence and/or estoppel (its eighth affirmative defense) and waiver (its ninth affirmative defense). D.I. 21 at 85–88 (¶¶ 70–79). Specifically, Gilead alleges the Complaint "is barred . . . by the doctrines of acquiescence and/or estoppel" because "the Government has encouraged both the public use and the prescription of Truvada® for PrEP purposes." *Id.* at 85–86 (¶¶ 70–71). It similarly alleges that the Government's claims are barred "by the equitable doctrine of implied waiver" in "seeking patent protection for the use of Truvada® for PrEP purposes, failing to disclose to Defendants that the Government was seeking such patent protection, and encouraging GSI to market Truvada® for PrEP purposes." *Id.* at 86 (¶¶ 73–74).

These equitable defenses should be dismissed. "The Supreme Court has stated that equitable estoppel will not lie against the government as against private litigants . . . [and it has] emphasized that it has 'reversed every finding of estoppel [against the government]' that has come before it." *Bokum v. Comm'r of Internal Revenue*, 992 F.2d 1136, 1141 (11th Cir. 1993) (citing *Heckler v. Cmty. Health Serv.*, 467 U.S. 51, 60 (1984) and quoting *OPM*, 496 U.S. at 422). "The case law is [] clear that if equitable estoppel is ever to apply to the Government, the justification for it must be compelling and must go beyond the showing a party would have to make against an ordinary opponent in an ordinary case." *Philip Morris*, 300 F. Supp. 2d at 66 (citing *ATC Petroleum, Inc. v. Sanders*, 860 F.2d 1104, 1111 (D.C. Cir. 1988)); *United States v. Walerko Tool & Eng'g Corp.*, *78*4 F. Supp. 1385, 1389 (N.D. Ind. 1992) ("A defendant may invoke estoppel against the federal government only in the most extraordinary circumstances, if ever.") (citation

omitted). Further, "[t]he party wishing to assert estoppel against the government must not only demonstrate 'each of the traditional elements of the doctrine,' but must also make 'a showing of an injustice . . . and lack of undue damage to the public interest.'" *Philip Morris*, 300 F. Supp. 2d at 70 (quoting *ATC Petroleum*, 860 F.2d at 1111) (emphasis added).

Gilead asserts that the Government encouraged the public to use a prophylactic regimen that CDC invented as a way to protect the public against the global HIV/AIDS epidemic and that this act justifies application of the doctrines of estoppel and waiver. D.I. 21 at ¶¶ 85–88 (¶¶ 70–79).[5] Specifically, Gilead pleads that the Government engaged in "affirmative misconduct" by "obtaining the HHS Patents," "encouraging the public to use the accused products in a manner that the Government alleges infringes the HHS Patents," *id.* at 86 (¶ 72), and thus "encourag[ing] GSI to engage in actions that the Government alleges would infringe their claims without disclosing the existence of the HHS Patents to GSI," *id.* at 88 (¶ 79).

But actions taken to protect the public welfare using a federally owned invention do not justify application of estoppel in this case. Only where a party has demonstrated affirmative, egregious government misconduct could a court consider the "rigid and sparing" application of estoppel against the government. *ATC Petroleum*, 860 F.2d at 1111; *OPM*, 496 U.S. at 421 (noting

[5] Gilead asserts that the government's actions have been "so inconsistent with an intent to enforce its rights as to induce a reasonable belief that such right has been relinquished," quoting *Core Wireless Licensing S.A.R.L. v. Apple Inc.*, 899 F.3d 1356, 1365 (Fed. Cir. 2018), but "[n]o estoppel arises from mere delay, acquiescence, or nonaction, even if it results in inducing expenditures." *United States v. Standard Oil Co.*, 20 F. Supp. 427, 454 (S.D. Cal. 1937) (citation omitted); *see also United States v. Washington*, 157 F.3d 630, 649 (9th Cir. 1998) (noting that neither "laches [n]or estoppel [are] available" in rejecting a laches argument where the sovereign had waited 135 years to bring the claim); *Hatchett v. United States*, 330 F.3d 875, 887 (6th Cir. 2003) (collecting cases). Nor does "estoppel arise[] from inconsistent action." *Standard Oil*, 20 F. Supp. at 454 (citations omitted)); *see also Fano v. O'Neill*, 806 F.2d 1262, 1265 (5th Cir. 1987) ("to state a cause of action for estoppel against the government, a private party must allege more than mere negligence, delay, inaction, or failure to follow an internal agency guideline."); *Schweiker v. Hansen*, 450 U.S. 785, 789 (1981).

the "possibility . . . that some type of 'affirmative misconduct' might give rise to estoppel against the government.") (emphasis added); *accord Portmann v. United States*, 674 F.2d 1155, 1165–67 (7th Cir. 1982). And where, as here, the United States "exercises its sovereign powers for the benefit of the public," the Government is outside the reach of estoppel. *Deltona Corp. v. Alexander*, 682 F.2d 888, 891–92 (11th Cir. 1982); *United States v. Florida*, 482 F.2d 205, 209 (5th Cir. 1973); *Hicks v. Harris*, 606 F.2d 65, 68 (5th Cir. 1979); *but see Moody v. United States*, 783 F.2d 1244, 1246 (5th Cir. 1986) (citation omitted).

ii. Unclean Hands

Gilead pleads unclean hands (its fourth affirmative defense) based on the same allegations underlying its estoppel defense, while also alleging, *inter alia*: (i) that the CDC failed to provide Gilead notice it was applying for a patent, as the Material Transfer Agreements (MTAs) required, and (ii) that a post-invention Clinical Trial Agreement (CTA) promised not to seek patent protection based on any inventions "that derive[d] from" use of the study drug in the clinical trial. D.I. 21 at 68 ¶ 6. But the affirmative defense of unclean hands, as an equitable defense, is generally barred by the district courts "for the same reason that estoppel is barred." *United States ex rel. Baker v. Cmty. Health Sys.*, No. CIV 05-279 WJ/WDS, 2011 U.S. Dist. LEXIS 165181, at *28 (D.N.M. Dec. 7, 2011) (citing *Worthington v. Anderson*, 386 F.3d 1314, 1319 (10th Cir. 2004)); *see also Pan Am. Co. v. United States*, 273 U.S. 456, 506 (1927). Specifically, "courts have held that the equitable doctrine of unclean hands may not be asserted against the United States when it acts in its sovereign capacity to protect the public welfare." *United States v. Vineland Chem. Co.*, 692 F. Supp. 415, 423 (D.N.J. 1988) (citation omitted).[6]

[6] Further, "[t]he doctrine of unclean hands 'may not be invoked against a government agency which is attempting to enforce a congressional mandate in the public interest.'" *Elecs. Warehouse*, 689 F. Supp. 73, 73 (quoting *SEC v. Gulf & W. Indus., Inc.*, 502 F. Supp. 343, 348 (D.D.C. 1980)),

Thus, this defense is not available to Gilead. Like estoppel, exceptions exist for an unclean hands defense but generally "require[] that the agency's misconduct be egregious and the resulting prejudice to the defendant rise to a constitutional level." *SEC v. Elecs. Warehouse, Inc.*, 689 F. Supp. 53, 73 (D. Conn. 1988). That is not the case here. Gilead pleads that "the Government has engaged in affirmative misconduct (*e.g.*, obtaining the HHS Patents in breach of the MTAs and CTA)," and Gilead has filed suit raising the same allegations of breach of contract in the Court of Federal Claims. *Gilead Sci., Inc., v. United States*, No. 1:20-cv-449C (Fed. Cl.). But such a breach of contract is not "egregious" nor does it cause "prejudice [that] rise[s] to a constitutional level." *Id.* at 73.[7]

iii. Failure to Mitigate

Gilead also pleads the Government's failure to mitigate the "harm" it has "sustained, if any" (its thirteenth affirmative defense). D.I. 21 at 89 (¶ 83). The rationale and concerns surrounding application of this equitable defense are identical to those for unclean hands. Circuit courts have refused to consider affirmative defenses like failure to mitigate damages because those

aff'd, 891 F.2d 457 (2d Cir. 1989) (citation omitted); *see also Pan Am. Co.*, 273 U.S. at 506 (equitable defense cannot "frustrate the purpose of its laws or . . . thwart public policy"). *EEOC v. Hibbing Taconite Co.*, 266 F.R.D. 260, 269 (D. Minn. 2009) ("A survey of cases on the question discloses that Courts have been hesitant to allow the defense of unclean hands against the Government when it acts in the interest of the public."). *See also* 35 U.S.C. § 200 (setting out the federal policy "ensur[ing] that the Government obtains sufficient rights in federally supported inventions to meet the needs of the Government and protect the public against nonuse or unreasonable use of inventions.").

[7] Notably, Gilead's unclean hands defense is now pled as a creature of contract. The MTAs are governed by federal law as applied in federal courts in the District of Columbia, *see, e.g.*, D.I. 21-1, Ex. B at ¶ 10, and the CTA is also governed by federal law, *see* D.I. 21-2, Ex. S at § 13. In the District of Columbia, the doctrine of unclean hands "has no applicability in an action for damages." *Truitt v. Miller*, 407 A.2d 1073, 1079–80 (D.C. 1979) (citation omitted) (citation omitted); *see also Manufacturers' Fin. Co. v. McKey*, 294 U.S. 442, 451 (1935); *Zanders v. Reid*, 980 A.2d 1096, 1101 (D.C. 2009).

defenses would require second-guessing of governmental decisions grounded in social, economic, or political policy. *See, e.g., FDIC v. Mijalis*, 15 F.3d 1314, 1324 (5th Cir. 1994); *FDIC v. Oldenburg*, 38 F.3d 1119, 1121-22 (10th Cir. 1994); *FDIC v. Bierman*, 2 F.3d 1424, 1441 (7th Cir. 1993). The severe public health concerns surrounding the HIV/AIDS epidemic and the Government's continuing efforts to promote access to and use of PrEP medications by at-risk populations are precisely the sort of social and policy decisions that should be free from the second-guessing Gilead's defense requires. More specifically, this should include Government efforts to patent and license innovative PrEP regimens to commercial entities like Gilead and, in turn, to enforce its patents when necessary to protect the public's investment and interest in its inventions. This is the subject matter of the present suit and should be insulated from assertions of a failure to mitigate.

Gilead pleads few specifics surrounding this defense, *see* D.I. 21 at 89 (¶¶ 83–84), but asserts "affirmative misconduct" on behalf of the Government by "obtaining the HHS Patents in violation of the CTA and without providing the disclosure required by the MTAs and first disclosing them only years after encouraging GSI to undertake the actions that it now contends to be infringing." *Id.* at ¶ 84.

This defense also sounds in contract. But, more importantly, even accepting Gilead's position, as the Tenth Circuit highlighted in an agency context, "nothing could be more paradoxical or contrary to sound policy than to hold that it is the public which must bear the risk of errors of judgment made by [FDIC] officials in attempting to save a failing institution—a risk which would never have been created but for defendants' wrongdoing in the first instance." *Oldenburg*, 38 F.3d at 1121 (quotation omitted). Here, Gilead is the infringing wrongdoer that has declined to license the Government's patents and to pay a royalty. *See* D.I. 1 (Compl.) at ¶¶ 232, 241. It would be

contrary to public policy to permit Gilead to assert a failure to mitigate based upon the Government's attempts to promote and license federally owned PrEP innovations. *See id.* at ¶¶ 175, 182.[8]

iv. Inequitable Conduct

Finally, Gilead also pleads inequitable conduct (its fifth affirmative defense). D.I. 21 at 77–84 (¶¶ 44–67). To the Government's knowledge, no court has previously had cause to consider whether the defense of inequitable conduct falls within the general exclusion of equitable affirmative defenses against sovereign suits. This is not surprising, as the Government does not frequently bring patent infringement claims and even less frequently is accused of inequitable conduct.

Regardless, this narrow equitable defense does not warrant a departure from the general exclusion principles for equitable defenses discussed above. The strength of the prohibition on such traditional equitable defenses, like laches, or the closely related doctrine of unclean hands, immediately informs the unavailability of an inequitable conduct defense. The Federal Circuit has long noted that "[t]he concept of inequitable conduct in patent procurement derives from the equitable doctrine of unclean hands." *Demaco Corp. v. F. Von Langsdorff Licensing, Ltd.*, 851 F.2d 1387, 1394 (Fed. Cir. 1988); *see also Therasense, Inc. v. Becton, Dickinson & Co.*, 649 F.3d 1276, 1285 (Fed. Cir. 2011); *Consol. Aluminum Corp. v. Foseco Int'l Ltd.*, 910 F.2d 804, 812 (Fed.

[8] Courts are quick to strike such improper defenses. *New York v. UPS*, 160 F. Supp. 3d 629, 645 (S.D.N.Y. 2016) (noting that defendant "cite[d] no case in which a court determined that it would be proper to reduce a government entity's damages for failure to mitigate where that government entity was acting in a public enforcement role."); *see also Trepel v. Dippold*, No. 04 Civ. 8310 (DLC), 2006 U.S. Dist. LEXIS 78050, at *23 (S.D.N.Y. Oct. 27, 2006) (recognizing that "the duty to mitigate does not apply to intentional injuries where there is malice and willful intent to injure"). The Government has pled willful infringement of the Patents-in-Suit. Further, as with unclean hands, failure to mitigate is a creature of contract, and, accordingly, the concerns identified *supra* note 7 are appropriate to consider in support of striking the defense of failure to mitigate.

Cir. 1990). Accordingly, the principles that exclude unclean hands similarly prohibit Gilead's assertion of inequitable conduct here. *United States v. Cty. Nursing Servs. of Tex.*, No. 4:10-CV-2277, 2016 U.S. Dist. LEXIS 9652, at *8 (S.D. Tex. Jan. 27, 2016). Gilead has not pled facts sufficient to justify a departure from this general exclusion.

CONCLUSION

The United States is statutorily authorized to "protect and administer" its rights in the federally owned Patents-in-Suit. 35 U.S.C. § 207(a)(3). The present suit was brought to protect the public's interest and defend against Gilead's willful infringement on publicly-held property rights, and thus, for the reasons discussed above, Gilead may not successfully raise its affirmative equitable defenses as a matter of law. The United States respectfully moves this Court to exercise its just discretion and strike, pursuant to Fed. R. Civ. P. 12(f), the equitable affirmative defenses[9] from Gilead's Second Amended Answer.

[9] Specifically Gilead's Fourth Affirmative Defense (Unclean Hands), Fifth Affirmative Defense (Inequitable Conduct), Eighth Affirmative Defense (Acquiescence and/or Estoppel), Ninth Affirmative Defense (Implied Waiver), and Thirteenth Affirmative Defense (Failure to Mitigate).

Respectfully submitted,

JOSEPH H. HUNT
Assistant Attorney General

GARY L. HAUSKEN
Director

/s/ Walter W. Brown

WALTER W. BROWN
Senior Litigation Counsel
Commercial Litigation Branch
Civil Division
U.S. Department of Justice
Washington, D.C. 20530
Tel: (202) 307-0341
Fax: (202) 307-0345
walter.brown2@usdoj.gov

DAVID C. WEISS
United States Attorney

/s/ Laura D. Hatcher

LAURA D. HATCHER (DE Bar No. 5098)
Assistant United States Attorney
SHAMOOR ANIS
Assistant United States Attorney
1313 N. Market Street
P.O. Box 2046
Wilmington, Delaware 19899-2046
Tel: (302) 573-6277
Fax: (302) 573-6220
Laura.hatcher@usdoj.gov
Shamoor.anis@usdoj.gov

Attorneys for Plaintiff United States

Of Counsel:
PHILIP CHARLES STERNHELL
Assistant Director
PATRICK C. HOLVEY
Trial Attorney
Department of Justice

Dated: June 26, 2020

Exhibit 1

Charles M. Lizza
William C. Baton
Sarah A. Sullivan
SAUL EWING LLP
One Riverfront Plaza, Suite 1520
Newark, New Jersey 07102-5426
(973) 286-6700
clizza@saul.com

Attorneys for Plaintiffs
Gilead Sciences, Inc.
and Royalty Pharma Collection Trust

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

GILEAD SCIENCES, INC. and ROYALTY PHARMA COLLECTION TRUST, Plaintiffs, v. WATSON LABORATORIES, INC., ACTAVIS, INC., and ACTAVIS PLC, Defendants.	Civil Action No. _____ **COMPLAINT FOR PATENT INFRINGEMENT** **(Filed Electronically)**

Plaintiffs Gilead Sciences, Inc. ("Gilead") and Royalty Pharma Collection Trust ("Royalty Pharma") (collectively, "Plaintiffs"), for their Complaint against Defendants Watson Laboratories, Inc. ("Watson"), Actavis Inc., and Actavis plc (together with Watson, "Defendants"), hereby allege as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. §100, *et seq.*, arising from Watson's filing of an Abbreviated New Drug Application ("ANDA") with the United States Food and Drug Administration ("FDA") seeking

approval to commercially market a generic version of Gilead's LETAIRIS® drug product prior to the expiration of United States Reissue Patent No. RE42,462 ("the '462 patent" or "the patent-in-suit"). The '462 patent is owned by Royalty Pharma and exclusively licensed to Gilead.

THE PARTIES

2. Plaintiff Gilead is a company organized and existing under the laws of the State of Delaware, having its principal place of business at 333 Lakeside Drive, Foster City, California 94404.

3. Plaintiff Royalty Pharma is a Delaware trust, having its principal place of business at Rodney Square North, 1100 North Market Street, Wilmington, Delaware 19890.

4. On information and belief, Defendant Watson Laboratories, Inc. is a corporation organized and existing under the laws of the State of Nevada, having its principal place of business at Morris Corporate Center III, 400 Interpace Parkway, Parsippany, New Jersey, 07054.

5. On information and belief, Defendant Actavis, Inc. is a corporation organized and existing under the laws of the State of Nevada, having its principal place of business at Morris Corporate Center III, 400 Interpace Parkway, Parsippany, New Jersey 07054.

6. On information and belief, Defendant Watson is a wholly-owned subsidiary of Defendant Actavis, Inc.

7. On information and belief, Defendant Actavis plc is a corporation organized and existing under the laws of Ireland, having its principal place of business at 1 Grand Canal Square, Docklands, Dublin 2, Ireland.

8. On information and belief, Defendant Actavis, Inc. is a wholly-owned subsidiary of Defendant Actavis plc.

9. On information and belief, the acts of Watson complained of herein were done

at the direction of, with the authorization of, or with the cooperation, participation, or assistance of, or at least in part for the benefit of, Actavis, Inc. and Actavis plc.

10. On information and belief, Defendants manufacture and/or distribute generic drugs for sale and use throughout the United States, including in this Judicial District. On information and belief, Defendants also prepare and/or aid in the preparation and submission of ANDAs to the FDA.

JURISDICTION AND VENUE

11. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

12. This Court has personal jurisdiction over Watson by virtue of, *inter alia,* its systematic and continuous contacts with the State of New Jersey. On information and belief, Watson has its principal place of business in Parsippany, New Jersey, conducts business in this District, and purposefully avails itself of this forum by, among other things, making, shipping, using, offering to sell or selling, or causing others to use, offer to sell, or sell, pharmaceutical products in the State of New Jersey and deriving revenue from such activities. Also, on information and belief, Watson has customers in the State of New Jersey. Further, Watson is a wholly-owned subsidiary of Actavis, Inc., which has substantial contacts with the State of New Jersey.

13. On information and belief, Watson has been sued for patent infringement in this District and did not contest personal jurisdiction in this District in at least the following cases: *Jazz Pharmaceuticals, Inc., et al. v. Watson Laboratories, Inc.*, No. 14-7757; *Amarin Pharma, Inc., et al. v. Watson Laboratories, Inc.*, No. 14-3259; *Celgene Corporation v. Natco Pharma Limited, et al.*, No. 14-3126; *Supernus Pharmaceuticals, Inc. v. Actavis Inc., et al.*, No. 14-1981;

and *Bayer Pharma AG, et al. v. Watson Laboratories, Inc., et al.*, No. 14-1804. Further, on information and belief, Watson has purposefully availed itself of the benefits of this forum by filing counterclaims in at least four (4) of those actions: *Jazz Pharmaceuticals, Inc., et al. v. Watson Laboratories, Inc.*, No. 14-7757; *Amarin Pharma, Inc., et al. v. Watson Laboratories, Inc.*, No. 14-3259; *Celgene Corporation v. Natco Pharma Limited, et al.*, No. 14-3126; and *Bayer Pharma AG, et al. v. Watson Laboratories, Inc., et al.*, No. 14-1804.

14. This Court has personal jurisdiction over Actavis, Inc. by virtue of, *inter alia,* its systematic and continuous contacts with the State of New Jersey. On information and belief, Actavis, Inc. has its principal place of business in Parsippany, New Jersey, conducts business in this District, and purposefully avails itself of this forum by, among other things, making, shipping, using, offering to sell or selling, or causing others to use, offer to sell, or sell, pharmaceutical products in the State of New Jersey and deriving revenue from such activities. On information and belief, Actavis, Inc. is registered to do business in the State of New Jersey. Also, on information and belief, Actavis Inc. has customers in the State of New Jersey.

15. On information and belief, Actavis, Inc. has been sued for patent infringement in this District and did not contest personal jurisdiction in this District in at least the following cases: *Bayer Pharma AG, et al. v. Watson Laboratories, Inc., et al.*, No. 14-1804; *Noven Therapeutics, LLC v. Actavis Laboratories FL, Inc., et al.*, No. 14-6414; and *AstraZeneca AB, et al. v. Andrx Labs*, LLC*, et al.*, No. 14-8030. Further, on information and belief, Actavis, Inc. has purposefully availed itself of the benefits of this forum by filing counterclaims in at least one (1) of those actions: *Bayer Pharma AG, et al. v. Watson Laboratories, Inc., et al.*, No. 14-1804.

16. This Court has personal jurisdiction over Actavis plc by virtue of, *inter alia,* its systematic and continuous contacts with the State of New Jersey. On information and belief,

Actavis plc conducts business in this District, and purposefully avails itself of this forum by, among other things, making, shipping, using, offering to sell or selling, or causing others to use, offer to sell, or sell, pharmaceutical products in the State of New Jersey and deriving revenue from such activities. Also, on information and belief, Actavis plc has customers in the State of New Jersey.

17. On information and belief, Defendants plan to continue to maintain continuous and systematic contacts with the State of New Jersey, including, but not limited to, their aforementioned business of preparing generic pharmaceuticals (including Watson's Proposed Products, as defined in paragraph 23, *infra*) to distribute in the State of New Jersey.

18. On information and belief, Defendants share common officers and directors and are agents of each other and/or work in concert with each other with respect to the development, regulatory approval, marketing, sale, and distribution of pharmaceutical products throughout the United States, including into New Jersey.

19. Venue is proper in this Judicial District pursuant to 28 U.S.C. §§ 1391 and 1400(b).

THE PATENT-IN-SUIT

20. On June 14, 2011, the United States Patent and Trademark Office ("USPTO") duly and lawfully issued the '462 patent, entitled "Carboxylic Acid Derivatives, Their Preparation and Use." The '462 patent is a reissue of United States Patent No. 5,932,730, issued on August 3, 1999. A copy of the '462 patent is attached hereto as Exhibit A.

THE LETAIRIS® DRUG PRODUCT

21. Gilead holds an approved New Drug Application ("NDA") under Section 505(a) of the Federal Food Drug and Cosmetic Act ("FFDCA"), 21 U.S.C. § 355(a), for

ambrisentan tablets (NDA No. 22-081), which it sells under the trade name LETAIRIS®. The claims of the patent-in-suit cover, *inter alia*, carboxylic acid derivatives, including the compound ambrisentan.

22. Pursuant to 21 U.S.C. § 355(b)(1) and attendant FDA regulations, the patent-in-suit is listed in the FDA publication, "Approved Drug Products with Therapeutic Equivalence Evaluations" (the "Orange Book"), with respect to LETAIRIS®.

ACTS GIVING RISE TO THIS ACTION

23. Pursuant to Section 505 of the FFDCA, Watson filed ANDA No. 208-252 ("Watson's ANDA") seeking approval to engage in the commercial use, manufacture, sale, offer for sale or importation into the United States of ambrisentan tablets 5 mg and 10 mg ("Watson's Proposed Products"), before the patent-in-suit expires.

24. In connection with the filing of its ANDA as described in the preceding paragraph, Watson has provided a written certification to the FDA, as called for by Section 505 of the FFDCA, alleging that the claims of the patent-in-suit are invalid, unenforceable, and/or will not be infringed by the activities described in Watson's ANDA.

25. On or about February 23, 2015, Plaintiffs received written notice of Watson's ANDA certification ("Watson's Notice Letter"). Watson's Notice Letter alleged that the claims of the '462 patent are invalid, unenforceable, and/or will not be infringed by the activities described in Watson's ANDA. Watson's Notice Letter also informed Plaintiffs that Watson seeks approval to market Watson's Proposed Products before the '462 patent expires.

COUNT FOR INFRINGEMENT OF THE '462 PATENT

26. Plaintiffs repeat and reallege the allegations of paragraphs 1-25 as though fully set forth herein.

27. Watson's submission of its ANDA to obtain approval to engage in the commercial use, manufacture, sale, offer for sale, or importation of ambrisentan tablets into the United States, prior to the expiration of the '462 patent, constitutes infringement of one or more of the claims of that patent under 35 U.S.C. § 271(e)(2)(A).

28. There is a justiciable controversy between the parties hereto as to the infringement of the '462 patent.

29. Unless enjoined by this Court, upon FDA approval of Watson's ANDA, Defendants will infringe the '462 patent under 35 U.S.C. § 271(a) by making, using, offering to sell, importing into the United States, and/or selling Watson's Proposed Products in the United States.

30. Unless enjoined by this Court, upon FDA approval of Watson's ANDA, Defendants will induce infringement of the '462 patent under 35 U.S.C. § 271(b) by making, using, offering to sell, importing into the United States, and/or selling Watson's Proposed Products in the United States. On information and belief, upon FDA approval of Watson's ANDA, Defendants will intentionally encourage acts of direct infringement with knowledge of the '462 patent and knowledge that their acts are encouraging infringement.

31. Unless enjoined by this Court, upon FDA approval of Watson's ANDA, Defendants will contributorily infringe the '462 patent under 35 U.S.C. § 271(c) by making, using, offering to sell, importing into the United States, and/or selling Watson's Proposed Products in the United States. On information and belief, Defendants have had and continue to have knowledge that Watson's Proposed Products are especially adapted for a use that infringes the '462 patent and that there is no substantial noninfringing use for Watson's Proposed Products.

32. Plaintiffs will be substantially and irreparably damaged and harmed if Defendants' infringement of the '462 patent is not enjoined.

33. Plaintiffs do not have an adequate remedy at law.

34. This case is an exceptional one, and Plaintiffs are entitled to an award of their reasonable attorneys' fees under 35 U.S.C. § 285.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request the following relief:

(A) A Judgment that Defendants have infringed the '462 patent by submitting ANDA No. 208-252;

(B) A Judgment that Defendants have infringed, and that Defendants' making, using, selling, offering to sell, or importing into the United States Watson's Proposed Products will infringe one or more claims of the '462 patent;

(C) An Order that the effective date of FDA approval of ANDA No. 208-252 be a date which is not earlier than the later of the expiration of the '462 patent, or any later expiration of exclusivity to which Plaintiffs are or become entitled;

(D) Preliminary and permanent injunctions restraining and enjoining Defendants, their officers, agents, attorneys and employees, and those acting in privity or concert with them, from making, using, selling, offering to sell, or importing into the United States Watson's Proposed Products until after the expiration of the '462 patent, or any later expiration of exclusivity to which Plaintiffs are or become entitled;

(E) A permanent injunction, pursuant to 35 U.S.C. § 271(e)(4)(B), restraining and enjoining Defendants, their officers, agents, attorneys and employees, and those acting in privity or concert with them, from practicing any claim of the '462 patent, or from actively inducing or

contributing to the infringement of any claim of the ’462 patent, until after the expiration of the ’462 patent, or any later expiration of exclusivity to which Plaintiffs are or becomes entitled;

(F) A Declaration that the commercial manufacture, use, importation into the United States, sale, or offer for sale of Watson’s Proposed Products will directly infringe, induce, and/or contribute to infringement of the ’462 patent;

(G) To the extent that Defendants have committed any acts of infringement with respect to the inventions claimed in the ’462 patent, other than those acts expressly exempted by 35 U.S.C. § 271(e)(1), that Plaintiffs be awarded damages for such acts, together with interest;

(H) If Defendants engage in the commercial manufacture, use, importation into the United States, sale, or offer for sale of Watson’s Proposed Products prior to the expiration of the ’462 patent, a Judgment awarding damages to Plaintiffs resulting from such infringement, together with interest;

(I) A Judgment declaring that the ’462 patent remains valid and enforceable;

(J) Attorneys’ fees in this action as an exceptional case pursuant to 35 U.S.C. § 285;

(K) Costs and expenses in this action; and

(L) Such further and other relief as this Court may deem just and proper.

Respectfully submitted,

Dated: April 3, 2015

By: s/ Charles M. Lizza

Charles M. Lizza
William C. Baton
Sarah A. Sullivan
SAUL EWING
One Riverfront Plaza, Suite 1520
Newark, New Jersey 07102-5426
(973) 286-6700
clizza@saul.com

Attorneys for Plaintiffs
Gilead Sciences, Inc.
and Royalty Pharma Collection Trust

OF COUNSEL:

F. Dominic Cerrito
Eric C. Stops
Evangeline Shih
Gabriel Brier
Daniel C. Wiesner
Ashley M. Fry
QUINN EMANUEL URQUHART
& SULLIVAN, LLP
51 Madison Avenue
New York, NY 10010
(212) 849-7000

Attorneys for Plaintiff
Gilead Sciences, Inc.

Marshall Schmitt
MICHAEL BEST & FRIEDRICH LLP
Two Prudential Plaza,
180 North Stetson Avenue
Suite 2000
Chicago, Illinois 60601
(312) 596-5828

Attorneys for Plaintiff
Royalty Pharma Collection Trust

CERTIFICATION PURSUANT TO LOCAL CIVIL RULES 11.2 & 40.1

Pursuant to Local Civil Rules 11.2 and 40.1, I hereby certify that the matter in controversy is related to *Gilead Sciences, Inc., et al. v. Watson Laboratories, Inc., et al.*, Civil Action No. 15-289 (D. Del.). I further certify that, to the best of my knowledge, the matter in controversy is not the subject of any other action pending in any court, or of any pending arbitration or administrative proceeding.

Respectfully submitted,

Dated: April 3, 2015

By: s/ Charles M. Lizza

Charles M. Lizza
William C. Baton
Sarah A. Sullivan
SAUL EWING
One Riverfront Plaza, Suite 1520
Newark, New Jersey 07102-5426
(973) 286-6700
clizza@saul.com

Attorneys for Plaintiffs
Gilead Sciences, Inc.
and Royalty Pharma Collection Trust

OF COUNSEL:

F. Dominic Cerrito
Eric C. Stops
Evangeline Shih
Gabriel Brier
Daniel C. Wiesner
Ashley M. Fry
QUINN EMANUEL URQUHART & SULLIVAN, LLP
51 Madison Avenue
New York, NY 10010
(212) 849-7000

Attorneys for Plaintiff
Gilead Sciences, Inc.

Marshall Schmitt
MICHAEL BEST & FRIEDRICH LLP
Two Prudential Plaza,
180 North Stetson Avenue
Suite 2000
Chicago, Illinois 60601
(312) 596-5828

Attorneys for Plaintiff
Royalty Pharma Collection Trust

EXHIBIT A

US00RE42462E

(19) **United States**

(12) **Reissued Patent**

Riechers et al.

(10) **Patent Number: US RE42,462 E**

(45) **Date of Reissued Patent: Jun. 14, 2011**

(54) **CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE**

(75) Inventors: **Hartmut Riechers**, Neustadt (DE); **Dagmar Klinge**, Heidelberg (DE); **Wilhelm Amberg**, Friedrichsdorf (DE); **Andreas Kling**, Mannheim (DE); **Stefan Muller**, Speyer (DE); **Ernst Baumann**, Dudenhofen (DE); **Joachim Rheinheimer**, Ludwigshafen (DE); **Uwe Josef Vogelbacher**, Ludwigshafen (DE); **Wolfgang Wernet**, Hassloch (DE); **Liliane Unger**, Ludwigshafen (DE); **Manfred Raschack**, Weisenheim (DE)

(73) Assignee: **Abbott GmbH & Co. KG**, Wiesbaden (DE)

(21) Appl. No.: **12/481,594**

(22) PCT Filed: **Oct. 7, 1995**

(86) PCT No.: **PCT/EP95/03963**

§ 371 (c)(1),
(2), (4) Date: **Mar. 27, 1997**

(87) PCT Pub. No.: **WO96/11914**

PCT Pub. Date: **Apr. 25, 1996**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **5,932,730**
Issued: **Aug. 3, 1999**
Appl. No.: **08/809,699**
Filed: **Mar. 27, 1997**

(51) **Int. Cl.**

C07D 239/60	(2006.01)
C07D 239/96	(2006.01)
C07D 251/30	(2006.01)
C07D 403/12	(2006.01)

(52) **U.S. Cl.** **544/298**; 544/299; 544/300; 544/301; 544/302; 544/309; 544/310; 544/312; 544/314; 544/315; 544/316; 544/317; 544/318; 544/319; 544/322; 544/326; 544/327; 544/328; 544/329; 544/335

(58) **Field of Classification Search** 544/298, 544/299, 300, 301, 302, 309, 310, 312, 314, 544/315, 316, 317, 318, 319, 322, 326, 327, 544/328, 329, 335

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,178,663	A	1/1993	Harada et al.
5,270,289	A	12/1993	Harde et al.
5,318,945	A	6/1994	Baumann et al.
5,326,744	A	7/1994	Rheinheimer et al.
5,376,620	A	12/1994	Abe et al.
5,387,575	A	2/1995	Harada et al.
5,389,601	A	2/1995	Abe et al.
5,541,148	A	7/1996	Glock et al.
5,661,106	A	8/1997	Baumann et al.
5,703,017	A	12/1997	Baumann et al.
5,840,722	A	11/1998	Baumann et al.
5,969,134	A	10/1999	Riechers et al.
6,030,975	A	2/2000	Romerdahl et al.
6,197,780	B1	3/2001	Munter et al.
6,197,958	B1	3/2001	Riechers et al.
6,329,384	B1	12/2001	Munter et al.
6,352,992	B1	3/2002	Kirchengast et al.
6,559,338	B1	5/2003	Bernard et al.
6,600,043	B2	7/2003	Riechers et al.
6,677,465	B2	1/2004	Jansen
7,109,205	B2	9/2006	Riechers et al.
7,119,097	B2	10/2006	Riechers et al.
2006/0276474	A1	12/2006	Riechers et al.
2007/0203338	A1	8/2007	Riechers et al.

FOREIGN PATENT DOCUMENTS

DE	4029648	A1	3/1992
DE	4035758	A1	5/1992
DE	4035758	A1	5/1992
DE	4123469	A1	1/1993
DE	4201875	A1	7/1993
DE	43 13 412		10/1994
DE	4313412	A1	10/1994
DE	4313413	A1	10/1994
DE	43 35 950		4/1995
DE	4335950	A	4/1995
DE	43 13 413		10/1995
DE	4411225	A1	10/1995
EP	347 811		12/1989
EP	347811	A	12/1989
EP	400741		12/1990
EP	409368	A2	1/1991

(Continued)

OTHER PUBLICATIONS

Advanced Organic Chem., Third Ed., Jerry Mar. 1985, pp. 750, 863.
Agr. Biol. Chem., 40(5), 993-1000, 1976, on the Sterochemistry . . . Kogure et al.
Ciba-Geigy AG "Neue Selektiv-herbizide Mittel" Research Disclosure Journal (1994).
Chung, Vo Van et al., "Photochemical Reaction of Ethyl 3-Methyl-3-phenylgycidate in Methanol and Ether Solvents", Bulletin of the Chemical Society of Japan, vol. 49(1), 341-342 (1976).
Raschack et al., Journal of Cardiovascular Pharmacology (1995), 26 (Suppl. 3), S397-S399.

(Continued)

Primary Examiner — Bruck Kifle

(74) *Attorney, Agent, or Firm* — Lisa V. Mueller; Polsinelli Shughart PC

(57) **ABSTRACT**

Carboxylic acid derivatives



where R-R^6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.

23 Claims, No Drawings

FOREIGN PATENT DOCUMENTS

EP	481 512		4/1992
EP	481512	A	4/1992
EP	517 215		12/1992
EP	517215	A	12/1992
EP	548710		6/1993
EP	567014	A1	10/1993
EP	581184	A1	2/1994
EP	695295	B1	2/1996
EP	695296		2/2007
JP	SHO-51-4135	A1	1/1976
JP	H03-031266		2/1991
JP	H03-240777	A	10/1991
JP	2730021	A1	12/1992
WO	94/00987	A2	1/1994
WO	94/00987	A3	1/1994
WO	95/26716		10/1995
WO	96/00219	A1	1/1996
WO	PCT/US2008/009236		7/2008

OTHER PUBLICATIONS

Riechers et al., Journal of Medicinal Chemistry (1996), 39(11), 2123-8.

Yanagisawa et al., Nature, 332:411-415 (1988).

Yanagisawa et al., FEBS Letters, 231-440-444 (1988).

Hirata et al., Biochem. Biophys. Res. Commun., 154:868-875 (1988).

Japan J. Hypertension 12:79 (1989).

J. Vascular Med. Biology, 2:207 (1990).

Kanno et al., J. Am. Med. Association, 264, 2868b (1990).

Raschack et al. (J. Cardiovasc. Pharmacol. (1995), 26 (Suppl. 3), S397-S399.

Riechers et al. (J. Med. Chem. (1996), 39(11), 2123-8).

CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE

Matter enclosed in heavy brackets [ ] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.

Two (2) reissue applications have been co-filed for the reissue of U.S. Pat. No. 5,932,730. The reissue applications are U.S. Ser. No. 12/481,594 (the present application) and U.S. Ser. No. 12/481,598 (a co-filed reissue application), all of which are co-filed reissues of U.S. Pat. No. 5,932,730.

The present invention relates to novel carboxylic acid derivatives, their preparation and use.

Endothelin is a peptide which is composed of 21 amino acids and is synthesized and released by the vascular endothelium. Endothelin exists in three isoforms, ET-1, ET-2 and ET-3. ln the following text, "endothelin" or "ET" signifies one or all isoforms of endothelin. Endothelin is a potent vasoconstrictor and has a potent effect on vessel tone. lt is known that this vasoconstriction is caused by binding of endothelin to its receptor (Nature, 332, (1988) 411-415; FEBS Letters, 231, (1988) 440-444 and Biochem. Biophys. Res. Commun., 154, (1988) 868-875).

lncreased or abnormal release of endothelin causes persistent vasoconstruction in the peripheral, renal and cerebral blood vessels, which may lead to illnesses. lt has been reported in the literature that elevated plasma levels of endothelin were found in patients with hypertension, acute myocardial infarct, pulmonary hypertension, Raynaud's syndrome, atherosclerosis and in the airways of asthmatics (Japan J. Hypertension, 12, (1989) 79, J. Vascular Med. Biology 2, (1990) 207, J. Am. Med. Association 264, (1990) 2868).

Accordingly, substances which specifically inhibit the binding of endothelin to the receptor ought also to antagonize the various abovementioned physiological effects of endothelin and therefore be valuable drugs.

We have found that certain carboxylic acid derivatives are good inhibitors of endothelin receptors.

The invention relates to carboxylic acid derivatives of the formula l

I



where R is formyl, tetrazole [[sic]], nitrile [[sic]], [a COOH group] *—COOH* or a radical which can be hydrolyzed to —COOH, and the other substituents have the following meanings:

R^2 *is* hydrogen, hydroxyl, $—NH_2$, $—NH(C_1\text{-}C_4\text{-alkyl})$, $—N(C_1\text{-}C_4\text{-alkyl})_2$, halogen, $C_1\text{-}C_4$-alkyl, $C_1\text{-}C_4$-haloalkyl, $C_1\text{-}C_4$-alkoxy, $C_1\text{-}C_4$-haloalkoxy or $C_1\text{-}C_4$-alkylthio;

X *is* nitrogen or CR^{14} where R^{14} is hydrogen or [$C_{1\text{-}5}$] $C_1\text{-}C_5$-alkyl, or CR^{14} forms together with CR^3 a 5- or 6-membered alkylene or alkenylene ring which can be substituted by one or two [$C_{1\text{-}4}$] $C_1\text{-}C_4$-alkyl groups and in which in each case a methylene group can be replaced by oxygen, sulfur, —NH— or —N[$C_{1\text{-}4}$]($C_1\text{-}C_4$-alkyl)—;

R^3 *is* hydrogen, hydroxyl, $—NH_2$, $—NH(C_1\text{-}C_4\text{-}$[Alkyl] *alkyl*), $—N(C_1\text{-}C_4\text{-alkyl})_2$, halogen, $C_1\text{-}C_4$-alkyl, $C_1\text{-}C_4$-haloalkyl, $C_1\text{-}C_4$-alkoxy, $C_1\text{-}C_4$-haloalkoxy, —NH—O—[$C_{1\text{-}4}$]$C_1\text{-}C_4$-alkyl, $C_1\text{-}C_4$-alkylthio or CR^3 is linked to CR^{14} as indicated above to give a 5- or 6-membered ring;

R^4 and R^5 (which can be identical or different) *are*:

phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, $C_1\text{-}C_4$-alkyl, $C_1\text{-}C_4$-haloalkyl, $C_1\text{-}C_4$-alkoxy, $C_1\text{-}C_4$-haloalkoxy, phenoxy, $C_1\text{-}C_4$-alkylthio, amino, $C_1\text{-}C_4$-alkylamino or $C_1\text{-}C_4$-dialkylamino; or

phenyl or naphthyl, which are connected together in the ortho positions via a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an $—SO_2—$, —NH— or N-alkyl group, or $C_3\text{-}C_7$-cycloalkyl;

R^6 *is* hydrogen, $C_1\text{-}C_8$-alkyl, $C_3\text{-}C_6$-alkenyl, $C_3\text{-}C_6$-alkynyl or $C_3\text{-}C_8$-cycloalkyl, where each of these radicals can be substituted one or more times by: halogen, nitro, cyano, $C_1\text{-}C_4$-alkoxy, $C_3\text{-}C_6$-alkenyloxy, $C_3\text{-}C_6$-alkynyloxy, $C_1\text{-}C_4$-alkylthio, $C_1\text{-}C_4$-haloalkoxy, $C_1\text{-}C_4$-alkylcarbonyl, $C_1\text{-}C_4$-alkoxycarbonyl, [$C_{3\text{-}8}$] $C_3\text{-}C_8$-alkylcarbonylalkyl, $C_1\text{-}C_4$-alkylamino, di-$C_1\text{-}C_4$-alkylamino, phenyl or phenyl or phenoxy which is substituted one or more times, [eg.] *e.g.,* one to three times, by halogen, [mitro] *nitro*, cyano, $C_1\text{-}C_4$-alkyl, $C_1\text{-}C_4$-haloalkyl, $C_1\text{-}C_4$-alkoxy, $C_1\text{-}C_4$-haloalkoxy or $C_1\text{-}C_4$-alkylthio;

phenyl or naphthyl, each of which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, $C_1\text{-}C_4$-alkyl, $C_1\text{-}C_4$-haloalkyl, $C_1\text{-}C_4$-alkoxy, $C_1\text{-}C_4$-haloalkoxy, phenoxy, $C_1\text{-}C_4$-alkylthio, $C_1\text{-}C_4$-alkylamino, $C_1\text{-}C_4$-dialkylamino, dioxomethylene [[sic]] or dioxoethylene [[sic]]; *or*

a five- or six-membered heteroaromatic moiety containing one to three nitrogen atoms and/or one sulfur or oxygen atom, which can carry one to four halogen atoms and/or one or two of the following radicals: $C_1\text{-}C_4$-alkyl, $C_1\text{-}C_4$-haloalkyl, $C_1\text{-}C_4$-alkoxy, $C_1\text{-}C_4$-haloalkoxy, $C_1\text{-}C_4$-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: $C_1\text{-}C_4$-alkyl, $C_1\text{-}C_4$-haloalkyl, $C_1\text{-}C_4$-alkoxy, $C_1\text{-}C_4$-haloalkoxy and/or $C_1\text{-}C_4$-alkylthio;

with the proviso that R^6 can be hydrogen only when Z is not a single bond;

Y *is* sulfur [or], oxygen or a single bond;

Z *is* sulfur [or], oxygen or a single bond.

The compounds, and the intermediates for preparing them, such as lV and Vl, may have one or more asymmetrical substituted carbon atoms. Such compounds may be in the form of the pure enantiomers or pure diastereomers or a mixture thereof. The use of an enantiomerically pure compound as active substance is preferred.

The invention furthermore relates to the use of the abovementioned carboxylic acid derivatives for producing drugs, in particular for producing endothelin receptor inhibitors.

The invention furthermore relates to the preparation of the compounds of the formula lV in enantiomerically pure form. Enantioselective epoxidation of an olefin with two phenyl

substituents is known (J. Org. Chem. 59, 1994, 4378-4380). We have now found, surprisingly, that even ester groups in these systems permit epoxidation in high optical purity.

The preparation of the compounds according to the invention where Z is sulfur or oxygen starts from the epoxides IV, which are obtained in a conventional manner, [eg.] *e.g.,* as described in J. March, Advanced Organic Chemistry, 2nd ed., 1983, page 862 and page 750, from the ketones II or the olefins III:



Carboxylic acid derivatives of the general formula VI can be prepared by reacting the epoxides of the general formula IV ([eg.] *e.g.,* with R═ROOR^{10} [[sic]]) with alcohols or thiols of the general formula V where R^6 and Z have the meanings stated in claim **1**.



To do this, compounds of the general formula IV are heated with compounds of the formula V, in the molar ratio of about 1:1 to 1:7, preferably 1 to 3 mole equivalents, to 50-200° C., preferably 80-150° C.

The reaction can also take place in the presence of a diluent. All solvents which are inert toward the reagents used can be used for this purpose.

Examples of such solvents or diluents are water, aliphatic, alicyclic and aromatic hydrocarbons, which may in each case be chlorinated, such as hexane, cyclohexane, petroleum ether, naphtha, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichloroethylene, ethers such as diisopropyl ether, dibutyl ether, methyl tert-butyl ether, propylene oxide, dioxane and tetrahydrofuran, ketones such as acetone, methyl ethyl ketone, methyl isopropyl ketone and methyl isobutyl ketone, nitriles such as acetonitrile and propionitrile, alcohols, such as methanol, ethanol, isopropanol, butanol and ethylene glycol, esters such as ethyl acetate and amyl acetate, amides such as dimethylformamide, dimethylacetamide and N-methylpyrrolidone, sulfoxides and sulfones, such as dimethyl sulfoxide and sulfolane, bases such as pyridine, cyclic ureas such as 1,3-dimethylimidazolidin-2-one and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone.

The reaction is preferably carried out at a temperature in the range from 0° C. to the boiling point of the solvent or mixture of solvents.

The presence of a catalyst may be advantageous. Suitable catalysts are strong organic and inorganic acids, and Lewis acids. Examples thereof are, inter alia, sulfuric acid, hydrochloric acid, trifluoroacetic acid, p-toluenesulfonic acid, boron trifluoride etherate and titanium(IV) alcoholates.

Compounds of the formula VI where R^4 and R^5 are cycloalkyl can also be prepared by subjecting compounds of the formula VI where R^4 and R^5 are phenyl, naphthyl, or phenyl or naphthyl substituted as described above, to a nuclear hydrogenation.

Compounds of the formula VI can be obtained in enantiomerically pure form by starting from enantiomerically pure compounds of the formula IV and reacting them in the manner described with compounds of the formula V.

It is furthermore possible to obtain enantiomerically pure compounds of the formula VI by carrying out a classical racemate resolution on racemic or diastereomeric compounds of the formula VI using suitable enantiomerically pure bases such as brucine, strychnine, quinine, quinidine, chinchonidine [[sic]], chinchonine [[sic]], yohimbine, morphine, dehydroabietylamine, ephedrine (−), (+), deoxyephedrine (+), (−), threo-2-amino-1-(p-nitrophenyl)-1,3-propanediol (+), (−), threo-2-(N,N-dimethylamino)-1-(p-nitrophenyl)-1,3-propanediol (+), (−) threo-2-amino-1-phenyl-1,3-propanediol (+), (−), α-methylbenzylamine (+), (−), α-(1-naphthyl)ethylamine (+), (−), α-(2-naphthyl)ethylamine (+), (−), aminomethylpinane, N,N-dimethyl-1-phenylethylamine, N-methyl-1-phenylethylamine, 4-nitrophenylethylamine, pseudoephedrine, norephedrine, norpseudoephedrine, amino acid derivatives, peptide derivatives.

The compounds according to the invention where Y is oxygen, and the remaining substituents have the meanings stated under the general formula I, can be prepared, for example, by reacting the carboxylic acid derivatives of the general formula VI where the substituents have the stated meanings with compounds of the general formula VII



where R^{15} is halogen or R^{16}—SO$_2$—, where R^{16} can be C$_1$-C$_4$-alkyl, C$_1$-C$_4$-haloalkyl or phenyl. The reaction preferably takes place in one of the abovementioned inert diluents with the addition of a suitable base, [ie.] *i.e.,* of a base which deprotonates the intermediate VI, in a temperature range from room temperature to the boiling point of the solvent.

Compounds of the formula VII are known, some of them can be bought, or they can be prepared in a generally known manner.

It is possible to use as *a* base an alkali metal or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride, a carbonate such as an alkali metal carbonate, [eg.] *e.g.,* sodium or potassium carbonate, an alkali metal or alkaline earth metal hydroxide such as sodium or potassium hydroxide, an organometallic compound such as butyllithium, or an alkali metal amide such as lithium diisopropylamide.

The compounds according to the invention where Y is sulfur, and the remaining substituents have the meanings stated under the general formula I, can be prepared, for example, by reacting carboxylic acid derivatives of the general formula VIII, which can be obtained in a known manner from compounds of the general formula VI and in which the substituents have the abovementioned meanings, with compounds of the general formula IX, where R^2, R^3 and X have the meanings stated under general formula I.



VIII IX

The reaction preferably takes place in one of the abovementioned inert diluents with the addition of a suitable base, [ie.] *i.e.,* a base which deprotonates the intermediate IX, in a temperature range from room temperature to the boiling point of the solvent.

It is possible to use as *a* base, besides those mentioned above, organic bases such as triethylamine, pyridine, imidazole or diazabicycloundecane [[sic]].

Carboxylic acid derivatives of the formula VIa (z in formula VI=direct linkage) can be prepared by reacting epoxides of the formula IV with cuprates of the formula XI:



XI VIa

The cuprates can be prepared as described in Tetrahedron Letters 23, (1982) 3755.

Compounds of the formula I can also be prepared by starting from the corresponding carboxylic acids, [ie.] *i.e.,* compounds of the formula I where R is COOH, and initially converting these in a conventional manner into an activated form, such as a halide, an anhydride or imidazolide, and then reacting the latter with an appropriate hydroxy compound HOR^{10}. This reaction can be carried out in the usual solvents and often requires addition of a base, in which case those mentioned above are suitable. These two steps can also be simplified, for example, by allowing the carboxylic acid to act on the hydroxy compound in the presence of a dehydrating agent such as a carbodiimide.

In addition, it is also possible for compounds of the formula I to be prepared by starting from the salts of the corresponding carboxylic acids, [ie.] *i.e.,* from compounds of the formula I where R is COR^1 and R^1 is OM, where M can be an alkali metal cation or the equivalent of an alkaline earth metal cation. These salts can be reacted with many compounds of the formula R^1-A where A is a conventional nucleofugic leaving group, for example halogen such as chlorine, bromine, iodine or aryl- or alkylsulfonyl which is unsubstituted or substituted by halogen, alkyl or haloalkyl, such as toluenesulfonyl and methylsulfonyl, or another equivalent leaving group. Compounds of the formula R^1-A with a reactive substituent A are known or can be easily obtained with general expert knowledge. This reaction can be carried out in conventional solvents and advantageously takes place with the addition of a base, in which case those mentioned above are suitable.

The radical R in formula I may vary widely. For example, R is a group

where R^1 has the following meanings:

a) hydrogen;

b) succinylimidoxy [[sic]];

c) a five-membered heteroaromatic moiety linked by a nitrogen atom, such as pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which may carry one or two halogen atoms, in particular fluorine and chlorine and/or one or two of the following radicals:

C_1-C_4-alkyl such as methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl, 2-butyl;

C_1-C_4-haloalkyl, in particular C_1-C_2-haloalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl;

C_1-C_4-haloalkoxy, in particular C_1-C_2-haloalkoxy such as difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-1,1,2-trifluoroethoxy and pentafluoroethoxy, in particular trifluoromethoxy;

C_1-C_4-alkoxy such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, in particular methoxy, ethoxy, 1-methylethoxy;

C_1-C_4-alkylthio such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-dimethylethylthio, in particular methylthio and ethylthio;

d) R^1 *is* furthermore a radical



where m is 0 or 1 and R^7 and R^8, which can be identical or different, have the following meanings:

hydrogen;

C_1-C_8-alkyl, in particular C_1-C_4-alkyl as mentioned above;

C_3-C_6-alkenyl such as 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-me-

thyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl and 1-ethyl-2-methyl-2-propenyl, in particular 2-propenyl, 2-butenyl, 3-methyl-2-butenyl and 3-methyl-2-pentenyl;

C_3-C_6-alkynyl such as 2-propynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1-methyl-2-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1-ethyl-1-methyl-2-propynyl, preferably 2-propynyl, 2-butynyl, 1-methyl-2-propynyl and 1-methyl-2-butynyl, in particular 2-propynyl; *or*

C_3-C_8-cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl [and], cycloheptyl, *and* cyclooctyl, where these alkyl, cycloalkyl, alkenyl and alkynyl groups can each carry one to five halogen atoms, in particular fluorine or chlorine and/or one or two of the following groups:

- C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkylthio, C_1-C_4-haloalkoxy as mentioned above, C_3-C_6-alkenyloxy, C_3-C_6-alkenylthio, C_3-C_6-alkynyloxy, C_3-C_6-alkynylthio, where the alkenyl and alkynyl constituents present in these radicals preferably have the abovementioned meanings;
- C_1-C_4-alkylcarbonyl such as, in particular, methylcarbonyl, ethylcarbonyl, propylcarbonyl, 1-methylethylcarbonyl, butylcarbonyl, 1- methylpropylcarbonyl, 2-methylpropylcarbonyl, 1,1-dimethylethylcarbonyl;
- C_1-C_4-alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, 1-methylethoxycarbonyl, butyloxycarbonyl, 1-methylpropyloxycarbonyl, 2-methylpropyloxycarbonyl, 1,1-dimethylethoxycarbonyl;
- C_3-C_6-alkenylcarbonyl, C_3-C_6-alkynylcarbonyl, C_3-C_6-alkenyloxycarbonyl and C_3-C_6-alkynyloxycarbonyl, where the alkenyl and alkynyl radicals are preferably defined as detailed above;
- phenyl, unsubstituted or substituted one or more times, [eg.] *e.g.,* one to three times, by halogen, nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy or C_1-C_4-alkylthio, such as 2-fluorophenyl, 3-chlorophenyl, 4-bromophenyl, 2-methylphenyl, 3-nitrophenyl, 4-cyanophenyl, 2-trifluoromethylphenyl, 3-methoxyphenyl, 4-trifluoroethoxyphenyl, 2-methylthiophenyl, 2,4-dichlorophenyl, 2-methoxy-3-methylphenyl, 2,4-dimethoxyphenyl, 2-nitro-5-cyanophenyl, 2,6-difluorophenyl;
- di-C_1-C_4-alkylamino such as, in particular, dimethylamino, dipropylamino, N-propyl-N-methylamino, N-propyl-N-ethylamino, diisopropylamino, N-isopropyl-N-methylamino, N-isopropyl-N-ethylamino, N-isopropyl-N-propylamino;
- R^7 and [R8] R^8 *are* furthermore phenyl which can be substituted by one or more, [eg.] *e.g.,* one to three, of the following radicals: halogen, nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy or C_1-C_4-alkylthio, as mentioned above in particular;
- or R^7 and R^8 together form a C_4-C_7-alkylene chain which is closed to form a ring, is unsubstituted or substituted, [eg.] *e.g.,* substituted by C_1-C_4-alkyl, and may contain a heteroatom selected from the group consisting of oxygen, sulfur or nitrogen, such as $—(CH_2)_4—$, $—(CH_2)_5—$, $—(CH_2)_6—$, $—(CH_2)_7—$, $—(CH_2)_2—O—(CH_2)_2—$, $—CH_2—S—(CH_2)_3—$, $—(CH_2)_2—O—(CH_2)_3—$, $—NH—(CH_2)_3—$, $—CH_2—NH—(CH_2)_2—$, $—CH_2—CH═CH—CH_2—$, $—CH═CH—(CH_2)—_3—$;

e) R^1 *is* furthermore a group



where k is 0, 1 and 2[.];

p is 1, 2, 3 and 4; and

R^9 is C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl or unsubstituted or substituted phenyl, as mentioned above in particular[.];

f) R^1 *is* furthermore a radical OR^{10}, where R^{10} is:

hydrogen, the cation of an alkali metal such as lithium, sodium, potassium or the cation of an alkaline earth metal such as calcium, magnesium and barium or an environmentally compatible organic ammonium ion such as tertiary C_1-C_4-alkylammonium or the ammonium ion;

C_3-C_8-cycloalkyl as mentioned above, which may carry one to three C_1-C_4-alkyl groups;

C_1-C_8-alkyl such as, in particular, methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbuty 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl, 2-ethylbutyl, 1-ethyl-2-methylpropyl, which can carry one to five halogen atoms, in particular fluorine and chlorine and/or one of the following radicals:

- C_1-C_4alkoxy, C_1-C_4-alkylthio, cyano, C_1-C_4-alkylcarbonyl, C_3-C_8-cycloalkyl, C_1-C_4-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, where the aromatic radicals in turn can carry in each case one to five halogen atoms and/or one to three of the following radicals: nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and/or C_1-C_4-alkylthio, as mentioned above in particular;
- [a] C_1-C_8-alkyl as mentioned above, which can carry one to five halogen atoms, in particular fluorine and/or chlorine, and carries one of the following

radicals: a 5-membered heteroaromatic moiety containing one to three nitrogen atoms, or a 5-membered heteroaromatic moiety containing a nitrogen atom and an oxygen or sulfur atom, which can carry one to four halogen atoms and/or one or two of the following radicals:

nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, phenyl, C_1-C_4-haloalkoxy and/or C_1-C_4-alkylthio. Particular mention may be made of: 1-pyrazolyl, 3-methyl-1-pyrazolyl, 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl, 3-phenyl-1-pyrazolyl, 4-phenyl-1-pyrazolyl, 4-chloro-1-pyrazolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3-methyl-1,2,4-triazol-1-yl, 5-methyl-1,2,4-triazol-1-yl, 1-benzotriazolyl, 3-isopropyl-5-isoxazolyl, 3-methyl-5-isoxazolyl, 2-oxazolyl, 2-thiazolyl, 2-imidazolyl, 3-ethyl-5-isoxazolyl, 3-phenyl-5-isoxazolyl, 3-tert-butyl-5-isoxazolyl;

[a] C_2-C_6-alkyl [group] which carries one of the following radicals in position 2: C_1-C_4-alkoxyimino, C_3-C_6-alkynyloxyimino, C_3-C_6-haloalkenyloxyimino or benzyloxyimino; *or*

[a] C_3-C_6-alkenyl or C_3-C_6-alkynyl [group], it being possible for these groups in turn to carry one to five halogen atoms;

R^{10} *is* furthermore a phenyl radical which can carry one to five halogen atoms and/or one to three of the following radicals: nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and/or C_1-C_4-alkylthio, as mentioned above in particular;

a 5-membered heteroaromatic moiety which is linked via a nitrogen atom, contains one to three nitrogen atoms and can carry one or two halogen atoms and/or one or two of the following radicals: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, phenyl, C_1-C_4-haloalkoxy and/or C_1-C_4-alkylthio. Particular mention may be made of: 1-pyrazolyl, 3-methyl-1-pyrazolyl, 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl, 3-phenyl-1-pyrazolyl, 4-phenyl-1-pyrazolyl, 4-chloro-1-pyrazolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3-methyl-1,2,4-triazol-1-yl, 5-methyl-1,2,4-triazol-1-yl, 1-benzotriazolyl, 3,4-dichloro-1-imidazolyl;

R^{10} *is* furthermore a group



where R^{11} and R^{12}, which can be identical or different, are:

C_1-C_8-alkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl, C_3-C_8-cycloalkyl, it being possible for these radicals to carry a C_1-C_4-alkoxy, C_1-C_4-alkylthio and/or an unsubstituted or substituted phenyl radical, as mentioned above in particular;

phenyl which can be substituted by one or more, [eg.] *e.g.,* one to three, of the following radicals: halogen, nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy or C_1-C_4-alkylthio, where these radicals are, in particular, those mentioned above;

or R^{11} and R^{12} together form a C_3-C_{12}-alkylene chain which can carry one to three C_1-C_4-alkyl groups and contain a heteroatom from the group consisting of oxygen, sulfur and nitrogen, as mentioned in particular for R^7 and R^8[.];

g) R^1 *is* furthermore a radical



where R^{13} is:

C_1-C_4-alkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl, C_3-C_8-cycloalkyl as mentioned above in particular, it being possible for these radicals to carry a C_1-C_4-alkoxy, C_1-C_4-alkylthio and/or a phenyl radical as mentioned above; *or*

phenyl, unsubstituted or substituted, in particular as mentioned above[.];

h) R^1 *is* a radical



where R^{13} has the abovementioned meaning.

R can furthermore be:

tetrazole [[sic]] or nitrile [[sic]].

In respect of the biological effect, preferred carboxylic acid derivatives of the general formula I, both as pure enantiomers and pure diastereomers or as mixture thereof, are those where the substituents have the following meanings:

R^2 *is* hydrogen, hydroxyl, $N(C_1$-C_4-alkyl$)_2$, [the] C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, C_1-C_4-alkylthio groups and halogen atoms mentioned in detail for R^1, especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy;

X *is* nitrogen or CR^{14} where

R^{14} is hydrogen or alkyl, or CR^{14} forms together with CR^3 a 4- to 5-membered alkylene or alkenylene ring in which, in each case, a methylene group can be replaced by oxygen or sulfur, such as —CH_2—CH_2—O—, —CH═CH—O—, —CH_2—CH_2—CH_2—O—, —CH═CH—CH_2O—, in particular hydrogen, —CH_2—CH_2—O—, —$CH(CH_3)$—$CH(CH_3)$—O—, —$C(CH_3)$═$C(CH_3)$—O—, —CH═$C(CH_3)$—O— or —$C(CH_3)$═$C(CH_3)$—S—;

R^3 [the] *is* hydrogen, hydroxyl, $N(C_1$-C_4-alkyl$)_2$, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, C_1-C_4-alkylthio groups and halogen atoms mentioned for R^1, especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy or R^3 is linked to R^{14} as mentioned above to give a 5- or 6-membered ring;

R^4 and R^5 *are* phenyl or naphthyl, which can be substituted by one or more, [eg.] *e.g.,* one to three, of the following radicals: halogen, nitro, cyano, hydroxyl, mercapto, amino, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, C_1-C_4-alkylthio, C_1-C_4-alkylamino, di-C_1-C_4-alkylamino, C_1-C_4-alkylcarbonyl, C_1C_4-

alkoxycarbonyl; phenyl or naphthyl, which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an —SO_2—, —NH— **[**or**]**, N-alkyl group, or C_3-C_7-cycloalkyl;

R^6 *is* C_1-C_8-alkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl or C_3-C_8-cycloalkyl as mentioned above in particular, it being possible for these radicals in each case to be substituted one or more times by: halogen, hydroxyl, nitro, cyano, C_1-C_4-alkoxy, C_3-C_6-alkenyloxy, C_3-C_6-alkynyloxy, C_1-C_4-alkylthio, C_1-C_4-haloalkoxy, C_1-C_4-alkylcarbonyl, hydroxycarbonyl, C_1-C_4-alkoxycarbonyl, C_1-C_4-alkylamino, di-C_1-C_4-alkylamino or unsubstituted or substituted phenyl or phenoxy, as mentioned above in particular;

phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, phenoxy, C_1-C_4-alkylthio, C_1-C_4-**[**akylamino [sic]**]** *alkylamino* or C_1-C_4-dialkylamino, as mentioned in particular for R^7 and R^4; *or*

a five- or six-membered heteroaromatic moiety which contains one to three nitrogen atoms and/or one sulfur or oxygen atom and which can carry one to four halogen atoms and/or one or two of the following radicals: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, C_1-C_4-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and/or C_1-C_4-alkylthio, as mentioned for R^4 in particular;

Y *is* sulfur, oxygen or a single bond;

Z *is* sulfur, oxygen, —SO—, —SO_2—or a single bond.

Particularly preferred compounds of the formula I, both as pure enantiomers and pure diastereomers or as mixture thereof, are those in which the substituents have the following meanings:

R^2 *is* C_1-C_4-alkyl, *or* C_1-C_4-alkoxy*;*

X *is* nitrogen or CR^{14}, where

R^{14} is hydrogen or alkyl, or CR^{14} forms together with CR^3 a 4- or 5-membered alkylene or alkenylene ring such as —CH_2—CH_2—CH_2—, —CH═CH—CH_2—, in which in each case a methylene group can be replaced by oxygen or sulfur, such as —CH_2—CH_2—O—, —CH═CH—O—, —CH_2—CH_2—CH_2—O—, —CH═CH—CH_2O—, in particular hydrogen, —CH_2—CH_2—O—, —$CH(CH_3)$—$CH(CH_3)$—O—, —$C(CH_3)$═$C(CH_3)$—O—, —CH═$C(CH_3)$—O— or —$C(CH_3)$═$C(CH_3)$—S—;

R^3 **[**the**]** *is* C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkylthio groups mentioned for R^1, or R^3 is linked to R^{14} as mentioned above to give a 5- or 6-membered ring;

R^4 and R^5 *are* phenyl (identical or different) which can be substituted by one or more, **[**eg.**]** *e.g.,* one to three, of the following radicals: halogen, nitro, hydroxyl, C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkylthio*;* or

R^4 and R^5 are phenyl groups which are connected together in the ortho positions by a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO_2, NH or N-alkyl group; or

R^4 and R^5 are C_3-C_7-cycloalkyl;

R^6 *is* C_1-C_8-alkyl, C_3-C_6-alkenyl or C_3-C_8-cycloalkyl, it being possible for these radicals in each case to be substituted one or more times by: halogen, hydroxyl, nitro, cyano, C_1-C_4-alkoxy, C_3-C_6-alkenyloxy, C_1-C_4-alkylthio; *or*

R^6 *is* phenyl or naphthyl, which can be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxyl, amino, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, phenoxy, C_1-C_4-alkylthio, C_1-C_4-akylamino **[**[sic]**]** or C_1-C_4-dialkylamino; *or*

R^6 *is* a five- or six-membered heteroaromatic moiety which contains a nitrogen atom and/or a sulfur or oxygen atom and which can carry one to four halogen atoms and/or one or two of the following radicals: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-alkylthio, phenyl, phenoxy or phenylcarbonyl, it being possible for the phenyl radicals in turn to carry one to five halogen atoms and/or one to three of the following radicals: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy and/or C_1-C_4-alkylthio;

Y *is* sulfur, oxygen or a single bond;

Z *is* sulfur, oxygen, —SO—, —SO_2— or a single bond.

The compounds of the present invention provide a novel therapeutic potential for the treatment of hypertension, pulmonary hypertension, myocardial infarct, angina pectoris, acute kidney failure, renal insufficiency, cerebral vasospasms, cerebral ischemia, subarachnoid hemorrhages, migraine, asthma, atherosclerosis, endotoxic shock, endotoxin-induced organ failure, intravascular coagulation, restenosis after angioplasty, benign prostate hyperplasia, or hypertension or kidney failure caused by ischemia or intoxication.

The good effect of the compounds can be shown in the following tests:

Receptor binding studies

Cloned human ET_A receptor-expressing CHO cells and guinea pig cerebellar membranes with >60% ET_B compared with ET_A receptors were used for binding studies.

The ET_A receptor-expressing CHO cells were grown in F_{12} medium containing 10% fetal calf serum, 1% glutamine, 100 U/ml penicillin and 0.2% streptomycin (Gibco BRL, Gaithersburg, Md., USA).

After 48 h, the cells were washed with PBS and incubated with 0.05% trypsin-containing PBS for 5 min. Neutralization was then carried out with F_{12} medium, and the cells were collected by centrifugation at 300×g. To **[**lyze**]** *lyse* the cells, the pellet was briefly washed with lysis buffer (5 mM Tris-llCl, pll 7.4 with 10% glycerol) and then incubated at a concentration of 107 cells/ml of lysis buffer at 4° C. for 30 min. The membranes were centrifuged at 20,000×g for 10 min, and the pellet was stored in liquid nitrogen.

Guinea pig cerebella were homogenized in a Potter-Elvejhem homogenizer and **[**[lacuna]**]** obtained by differential centrifugation at 1000×g for 10 min and repeated centrifugation of the supernatant at 20,000×g for 10 min.

Binding assays

For the ET_A and ET_B receptor binding assay, the membranes were suspended in incubation buffer (50 mM Tris-HCl, pH 7.4 with 5 mM $MnCl_2$, 40 μg/ml bacitracin and 0.2% BSA) at a concentration of 50 μg of protein per assay mixture and incubated with 25 pM **[**[1251]**]** $I^{125}I$-ET_1 (ET_A receptor assay) or 25 pM **[**[1251]**]** $I^{125}I$-RZ_3 (ET_B receptor assay) in the presence and absence of test substance at 25° C. The nonspecific binding was determined using **[**10^{-7}**]** 10^{-7} M ET_1. After 30 min, the free and bound radioligand were separated by filtration through GF/B glass fiber filters (Whatman, England) on a Skatron cell collector (Skatron, Lier, Norway) and the filters were washed with ice-cold Tris-HCl buffer, pH

7.4 with 0.2% BSA. The radioactivity collected on the filters was quantified using a Packard 2200 CA liquid scintillation counter.

Functional in vitro assay system to look for endothelin receptor (subtype A) antagonists

This assay system is a functional, cell-based assay for endothelin receptors. When certain cells are stimulated with endothelin 1 (ET1) they show an increase in the intracellular calcium concentration. This increase can be measured in intact cells loaded with calcium-sensitive dyes.

1-Fibroblasts which had been isolated from rats and in which an endogenous endothelin receptor of the A subtype had been detected were loaded with the fluorescent dye [Fura 2-an] *Fura 2-am* as follows: after trypsinization, the cells were resuspended in buffer A (120 mM NaCl, 5 mM KCl, 1.5 mM $MgCl_2$, 1 mM $CaCl_2$, 25 mM HEPES, 10 mM glucose, pH 7.4) to a density of 2×10^6/ml and incubated with Fura 2-am (2 μM), Pluronics F-127 (0.04%) [und] *and* DMSO (0.2%) at 37° C. in the dark for 30 min. The cells were then washed twice with buffer A and resuspended at 2×10^6/ml.

The fluorescence signal from 2×10^5 cells per ml with Ex/Em 380/510 was recorded continuously at 30° C. The test substances and, after an incubation time of 3 min, ET1 [[lacuna]] to the cells, the maximum change in the fluorescence was determined. The response of the cells to ET1 without previous addition of a test substance was used as control and was set equal to 100%.

Testing of ET antagonists in vivo

Male SD rats weighting 250-300 g were anesthetized with amobarbital, [artifically] *artificially* ventilated, vagotomized and pithed. The carotid artery and jugular vein were [catheterized [sic]] *catheterized*.

In control animals, intravenous administration of 1 μg/kg ET1 led to a distinct rise in blood pressure which persisted for a lengthy period.

The test animals received an i.v. injection of the test compounds (1 ml/kg) 5 min before the administration of ET1. To determine the ET-antagonistic properties, the rise in blood pressure in the test animals was compared with that in the control animals.

Endothelin-1-induced sudden death in mice

The principle of the test is the inhibition of the sudden heart death caused in mice by endothelin, which is probably induced by constriction of the coronary vessels, by pretreatment with endothelin receptor antagonists. Intravenous injection of 10 nmol/kg endothelin in a volume of 5 ml/kg of body weight results in death of the animals within a few minutes.

The lethal endothelin-1 dose is checked in each case on a small group of animals. If the test substance is administered intravenously, the endothelin-1 injection which was lethal in the reference group usually takes place 5 min thereafter. With other modes of administration, the times before administration are extended, where appropriate up to several hours.

The survival rate is recorded, and effective doses which protect 50% of the animals (ED 50) from endothelin-induced heart death for 24 h or longer are determined.

Functional test on vessels for endothelin receptor antagonists

Segments of rabbit aorta are, after an initial tension of 2 g and a relaxation time of 1 h in Krebs-Henseleit solution at 37° C. and pH 7.3-7.4, first induced to contract with K^+. After washing out, an endothelin dose-effect plot up to the maximum is constructed.

Potential endothelin antagonists are administered to other preparations of the same vessel 15 min before starting the endothelin dose-effect plot. The effects of the endothelin are calibrated as a % of the K^+-induced contraction. Effective endothelin antagonists result in a shift to the right in the endothelin dose-effect plot.

The compounds according to the invention can be administered orally or parenterally (subcutaneously, intravenously, intramuscularly, [intraperotoneally] *intraperitoneally*) in a conventional way. Administration can also take place with vapors or sprays through the nasopharyngeal space.

The dosage depends on the age, condition and weight of the patient and on the mode of administration. The daily dose of active substance is, as a rule, about 0.5-50 mg/kg of body weight on oral administration and about 0.1-10 mg/kg of body weight on parenteral administration.

The novel compounds can be used in conventional solid or liquid pharmaceutical forms, [eg.] *e.g.*, as uncoated or (film-) coated tablets, capsules, powders, granules, suppositories, solutions, ointments, creams or sprays. These are produced in a conventional way. The active substances can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, release-slowing agents, antioxidants and/or propellent gases (cf. H. Sucker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1991). The administration forms obtained in this way normally contain from 0.1 to 90% by weight of the active substance.

Synthesis examples

Example 1

Methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate

5 g (19.6 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate were dissolved in 50 ml of absolute methanol and, at 0° C., 0.1 ml of boron trifluoride etherate was added. The mixture was stirred at 0° C. for 2 h and at room temperature for a further 12 h. The solvent was distilled out, the residue was taken up in ethyl acetate, washed with sodium bicarbonate solution and water and dried over magnesium sulfate. After removal of the solvent by distillation there remained 5.5 g (88%) of a pale yellow oil.

Example 2

Methyl 2-hydroxy-3-phenoxy-3,3-diphenylpropionate

5 g (19.6 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate and 5.6 g (60 mmol) of phenol were heated together at 100° C. for 6 h. Removal of the excess phenol by distillation under high vacuum and purification of the residue by chromatography on silica gel with hexane/ethyl acetate mixtures resulted in 4.9 g (77%) of a pale yellow oil.

Example 3

Methyl 2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionate

2.86 g (10 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 40 ml of dimethylformamide, and 0.3 g (12 mmol) of sodium hydride was added. The mixture was stirred for 1 h and then 2.2 g (10 mmol) of 4,6-dimethoxy-2-methylsulfonylpyrimidine were added. After stirring at room temperature for 24 h, cautious hydrolysis was carried out with 10 ml of water, the pH was adjusted to 5 with acetic acid, and the solvent was removed by distillation under high vacuum. The residue was taken up in 100 ml of ethyl acetate, washed with water and dried over magne-

sium sulfate, and the solvent was distilled out. The residue was mixed with 10 ml of ether, and the resulting precipitate was filtered off with suction. After drying, 3.48 g (82%) of a white powder remained.

Melting point 81° C.

Example 4

2-(4,6-Dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid

2.12 g (5 mmol) of methyl 2-(4,6-dimethoxy-pyrimidin-2-yl-oxy)-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml of dioxane, 10 ml of 1N KOH solution were added, and the mixture was stirred at 100° C. for 3 h. The solution was diluted with 300 ml of water and extracted with ethyl acetate to remove unreacted ester. The aqueous phase was then adjusted to pH 1-2 with dilute hydrochloric acid and extracted with ethyl acetate. After drying over magnesium sulfate and removal of the solvent by distillation, the residue was mixed with an ether/hexane mixture, and the precipitate which formed was filtered off with suction. After drying, 1.85 g (90%) of a white powder remained.

Melting point 167° C.

Example 5

2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl sodium [sic] propionate

1.68 g (4 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenylpropionic acid are dissolved in 4 ml of 1N NaOH+100 ml of water. The solution is freeze-dried, and the sodium salt of the carboxylic acid used is obtained quantitatively.

10 g (34.9 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml each of methanol and glacial acetic acid, 1 ml of $RuO(OH)_2$ in dioxane was added, and hydrogenation was carried out with H_2 in an autoclave at 100° C. under 100 bar for 30 h. The catalyst was filtered off, the mixture was concentrated, mixed with ether and washed with NaCl solution, and the organic phase was dried and concentrated. 10.1 g of methyl 3,3-dicyclohexyl-2-hydroxy-3-methoxypropionate were obtained as an oil.

Example 7

Methyl 2-[(4,6-dimethoxy-pyrimidin-2-yl)thio]-3-methoxy-3,3-diphenylpropionate **[**[sic]**]**

7.16 g (25 mmol) of methyl 2-hydroxy-3-methoxy-3,3-diphenylpropionate were dissolved in 50 ml of dichloromethane, 3 g (30 mmol) of triethylamine were added, and 3.2 g (28 mmol) of methanesulfonyl chloride were added dropwise while stirring. The mixture was stirred at room temperature for 2 h, washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The residue was taken up in DMF and added dropwise at 0° C. to a suspension of 12.9 g (75 mmol) of 4,6-dimethoxypyrimidine-2-thiol and 8.4 g (100 mmol) of sodium bicarbonate in 100 ml of DMF. After stirring at room temperature for 2 h and at 60° C. for a further 2 h, the mixture was poured into 1 liter of ice-water, and the resulting precipitate was filtered off with suction. After drying, 3.19 g (29%) of a white powder remained.

Example 8

Methyl 2-hydroxy-3,3-diphenylbutyrate

1.5 g (5.9 mmol) of methyl 3,3-diphenyl-2,3-epoxypropionate dissolved in 10 ml of absolute ether were added dropwise to a cup-rate solution which had been prepared from 635 mg (7 mmol) of copper(l) cyanide dissolved in 10 ml of absolute ether and 8.14 ml (13 mmol) of a 1.6 normal methyllithium solution and had been cooled to −78° C. The solution was stirred at −78° C. for 1 h and then allowed to warm to room temperature. lt was subsequently diluted with 100 ml of ether and 100 ml of water, and the ether phase was washed with dilute citric acid and with sodium bicarbonate solution and dried over magnesium sulfate. The crude product was purified by chromatography on silica gel with cyclohexane/ethyl acetate mixtures to result in 250 mg (16%) of a pale yellow oil.

Example 9

2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid

91.11 g (0.5 mol) of benzophenone and 45.92 g (0.85 mol) of sodium methoxide were suspended in 150 ml of methyl tert-butyl ether (MTB) at room temperature. After cooling to −100° C., 92.24 g (0.85 mol) of methyl chloroacetate were added in such a way that the internal temperature rose to 40° C. while continuing to cool in a bath at −10° C. The mixture was then stirred without cooling at the autogenous temperature for one hour. After addition of 250 ml of water and brief stirring, the aqueous phase was separated off. The MTB phase was washed with 250 ml of dilute sodium chloride solution. After the solvent had been changed to methanol (250 ml), a solution of 1 g of p-toluenesulfonic acid in 10 ml of methanol was added at room temperature. The mixture was stirred at autogenous temperature for one hour and then heated to reflux. While distilling out the methanol, 400 g of a 10% strength sodium hydroxide solution was added dropwise, and finally 60 ml of water were added. The methanol was distilled out until the bottom temperature reached 97° C. After cooling to 55° C., 190 ml of MTB were added and the mixture was acidified to pH 2 with about 77 ml of concentrated HCl. After cooling to room temperature, the aqueous phase was separated off and the organic phase was concentrated by distilling out 60 ml of **[**MtB [sic]**]** *MTB*. The product was crystallized by adding 500 ml of heptane and slowly cooling to room temperature. The coarsely crystalline solid was filtered off with suction, washed with heptane and dried to constant weight in a vacuum oven at 40° C.

Yield: 108.9 g (80%), HPLC >99.5% area.

Example 10

S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (racemate resolution with L-proline methyl ester)

148.8 g of a 30% strength methanolic sodium methanolate solution (0.826 mol) were added dropwise to 240 g of a 57% strength methanolic L-proline methyl ester hydrochloride solution (0.826 mol) at room temperature, and 2.41 of MTB and 225 g (0.826 mol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid were added. After 2680 ml of MTB/methanol mixture had been distilled out with simultaneous dropwise addition of 2.4 l of MTB, the mixture was slowly cooled to room temperature, the crystals (R-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid x L-proline methyl (ester) were filtered off with suction, and the solid was washed with 150 ml of MTB. The filtrate was concentrated by distilling out 1.5 l of MTB, and 1.0 l of water was added. The pH was adjusted

to 1.2 with concentrated hydrochloric acid at room temperature and, after stirring and phase separation, the aqueous phase was separated off and extracted with 0.4 l of MTB. The combined organic phases were extracted with 0.4 l of water. The residue after the MTB had been stripped off was dissolved in 650 ml of toluene under reflux, and the product was crystallized by seeding and slow cooling. Filtration with suction, washing with toluene and drying in a vacuum oven resulted in 78.7 g of S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid (yield 35% based on the racemate).

Chiral HPLC: 100% pure; HPLC: 99.8%

Example 11

S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (racemate resolution with (S)-1-(4-nitrophenyl)ethylamine)

30.5 g (0.184 mol) of (S)-1-(4-nitrophenyl)ethylamine were added to 100 g (0.368 mol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid in 750 ml of acetone and 750 ml of MTB under reflux, the mixture was seeded, boiled under reflux for one hour and slowly cooled to room temperature for crystallization. The crystals (S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid x (S)-1-(4-nitrophenyl) ethylamine) were filtered off with suction and washed with MTB. The residue was suspended in 500 ml of water and 350 ml of MTB and then the pH was adjusted to 1.2 with concentrated hydrochloric acid at room temperature, and, after stirring and phase separation, the aqueous phase was separated off and extracted with 150 ml of MTB. The combined organic phases were extracted with 100 ml of water. 370 ml of MTB were distilled out and then 390 ml of n-heptane were added under reflux, and the mixture was slowly cooled to room temperature while the product crystallized. Filtration with suction, washing with n-heptane and drying in a vacuum oven resulted in 35.0 g of S-2-hydroxy-3-methoxy-3,3-diphenylpropionic acid (yield 35% based on the racemate).

Chiral HPLC: 100% pure; HPLC: 99.8%

Example 12

Benzyl 3-methoxy-2-(4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionate

24.48 g (90 mmol) of 3-methoxy-3,3-diphenyl-2-hydroxypropionic acid were dissolved in 150 ml of DMF, and 13.7 g (99 mmol) of potassium carbonate were added. The suspension was stirred at room temperature for 30 min. Then 10.7 ml (90 mmol) of benzyl bromide were added dropwise over the course of 5 min, and the mixture was stirred for 1 h, during which the temperature rose to 32° C.

To this mixture were successively added 24.84 g (180 mmol) of K_2CO_3 and 20.52 g (90 mmol) of 2-methanesulfonyl-4-methoxy-6,7-dihydro-5H-cyclopentapyridine [[sic]], and the mixture was stirred at 80° C. for 3 h.

For workup, the contents of the flask were diluted with about 600 ml of H_2O and cautiously acidified with concentrated HCl, and 250 ml of ethyl acetate were added. 31.4 g of pure product precipitated and were filtered off.

The ethyl acetate phase was separated from the mother liquor, the aqueous phase was extracted again with ethyl acetate, and the combined organic phases were concentrated. The oily residue (19 g) was purified by chromatography (cyclohexane/ethyl acetate=9/1) to result in a further 10.5 g of pure product.

Total yield: 41.9 g (82.2 mmol)=91%; Melting point 143-147° C.; MS: MH^+=511

Example 13

3-Methoxy-2-(4-methoxy-(6,7-dihydro-5H-cyclopentapyrimidin-2-yl-oxy)-3,3-diphenylpropionic [[sic]] acid

40 g (78.4 mmol) of benzyl 3-methoxy-2-(4-methoxy-6,7-dihydro-5H-cyclopentapyrimidin-2-yloxy)-3,3-diphenylpropionate were dissolved in 400 ml of ethyl acetate/methanol (4:1), about 500 mg of palladium on active carbon (10%) were added, and the mixture was exposed to a hydrogen atmosphere until no further gas was taken up. The catalyst was filtered off, the solution was evaporated, and the residue was crystallized from ether.

Example 14

Ethyl 2S-3,3-diphenyloxirane-2-carboxylate

2.57 g (10.2 mnol) of ethyl 3,3-diphenylacrylate and 464 mg of 4-phenylpyridine N-oxide were dissolved in 24 ml of methylene chloride, and 432 mg (6.5 mol %) of (5,5)-(+)-N,N'-bis(3,5-ditert-butylsalicylidene)-1,2-cyclohexanediaminomanganese(lll) chloride were added. While cooling in ice, 6.4 ml of a 12% strength sodium hypochloride [[sic]] solution were added, and the mixture was stirred while cooling in ice for 30 min and at room temperature overnight. The solution was diluted to 200 ml with water, extracted with ether, dried and evaporated. 2.85 g of a colorless oil were obtained. Purification by [NPLC [sic]] *HPLC* (cyclohexane:ethyl acetate=9:1) resulted in 1.12 g of oil with an enantiomer ratio of about 8:1 in favor of the S configuration.

^{1}H-NMR [$CDCl_3$], δ=1.0 (t, 3H); 3.9 (m, 3H); 7.3 (m, 10H)

Example 15

2-Methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidin-4-ol [[sic]]

46.9 g (330 mmol) of methyl cyclopentanone-2-carboxylate and 53.5 g (192 mmol) of 5-methylisothiourea [[sic]] sulfate were successively added to 29.6 g (528 mmol) of KOH in 396 ml of methanol, and the mixture was stirred at room temperature overnight, acidified with 1N hydrochloric acid and diluted with water. The crystals which separated out were filtered off with suction and dried. 20 g of crystals were obtained.

Example 16

[sulfanyl] *Sulfanyl* 4-[Chloro] *chloro*-2-methyl-6,7-dihydro-5H-cyclopentapyrimidine [[sic]]

255 ml of phosphorus oxychloride were added to 20 g (110 mmol) [[lacuna]], and the mixture was stirred at 80° C. for 3 hours. Phosphorus oxychloride was evaporated off, ice was added to the residue, and the crystals which separated out were filtered off with suction. 18.5 g of a brownish solid were obtained.

Example 17

4-Methoxy-2-methylsulfonyl-6,7-dihydro-5ll-cyclopentapyrimidine [[sic]]

18.05 g (90 mmol) of 4-chloro-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine [[sic]] were dissolved in 200 ml of methanol. At 45° C., 16.7 g of sodium methoxide (as 30% strength solutions [[sic]] in methanol) were added dropwise, and the mixture was stirred for 2 hours. The solution was evaporated, taken up in ethyl acetate and acidified with dilute hydrochloric acid, and the ethyl acetate extract was evaporated. 15.5 g of an oil remained.

^{1}H-NMR [DMSO], δ=2.1 (quintet, 2H); 2.5 (s, 3H); 2.8 (dt, 4H); 3.9 (s, 3H) ppm

Example 18

2-Methylsulfonyl-4-methoxy-6,7-dihydro-5H-cyclopento-pyrimidine [[sic]]

15 g (76.2 mmol) of 4-methoxy-2-methylsulfonyl-6,7-dihydro-5H-cyclopentapyrimidine [[sic]] were dissolved in 160 ml of glacial acetic acid/methylene chloride (1:1), and 1.3 g of sodium tungstate were added. At 35° C., 17.5 ml (170 ml [[sic]]) of a 30% strength H_2O_2 solution were added dropwise. The mixture was then diluted with 500 ml of water and 100 ml of methylene chloride, and the organic phase was separated off, dried and evaporated. 14 g of oil remained and were crystallized from ether.

^{1}H-NMR [$CDCl_3$], δ=2.2 (quintet, 2H); 3.0 (dt., 4H); 3.3 (s, 3H); 4.1 (s, 3H) ppm

Example 19

1-Benzenesulfonyl-3-(4,6-dimethoxy-2-pyrimidinyloxy)-4-methoxy-4,4-diphenyl-2-butanone

0.37 g (2.4 mmol) of phenyl methane [[sic]] sulfone were dissolved in 10 ml of dry THF and then, at −70° C., 2 eq. of butyllithium (2.94 ml; 1.6 molar solution in hexane) were added dropwise. After 1 h at −70° C., 1 g (2.4 mmol) of methyl 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenylpropynoate [[sic]] dissolved in 5 ml of THF was added dropwise. The reaction mixture was then stirred at −70° C. for 1 h and at −10° C. for 1 h and then warmed to room temperature. For workup, about 10 ml of saturated NH_4Cl solution were added dropwise, thorough extraction with ethyl acetate was carried out, and the combined organic phases [[lacuna]] with-saturated N-Cl [[sic]] solution and dried over Na_2SO_4. The residue obtained after drying and concentration was purified by chromatography on silica gel (n-heptane/ethyl acetate 15%→30%) and subsequently [MPLC] *HPLC* on RP silica gel (acetonitrile/H_2O+TFA); 0.3 g of a white amorphous powder was obtained as product.

Example 20

3,3-Diphenyloxiram-2-carbonitrile [[sic]]

3.1 g (54.9 mmol) of sodium methoxide were suspended in 20 ml of dry THF and then, at −10° C., a mixture of 5 g (27.4 mmol) of benzophenone and 4.2 g (54.9 mmol) of chloroacetonitrile was added dropwise.

The reaction mixture was stirred at −10° C. for about 2 h, then poured into water and extracted several times with ethyl acetate. The combined organic phases were dried over Na_2SO_4 and concentrated, and the residue was purified by chromatography on silica gel (n-heptane/ethyl acetate).

Yield: 1.2 g (20%)

^{1}H-NMR [$CDCl_3$], δ=3.9 (s, 1H); 7.4-7.5 (m, 10 H) ppm

Example 21

2-Hydroxy-3-methoxy-3,3-diphenylpropionitrile

6.5 [[lacuna]] *g* (29.4 mmol) of 3,3-diphenyloxirane-2-carbonitrile were dissolved in 60 ml of methanol and, at 0° C., about 2 ml of boron triffuoride etherate solution were added. The mixture was stirred further at 0° C. for 1 h and then at room temperature overnight. For workup it was diluted with diethyl ether and washed with saturated NaCl solution, and the organic phase was dried over Na_2SO_4 and concentrated.

The residue comprised 7.3 g of a white amorphous powder which was used directly in the subsequent reactions.

^{1}H-NMR [[CDC_{13}]] */$CDCl_3$/*, δ=2.95 (broad s, OH), 3.15 (s, 3H), 5.3 (s, 1H), 7.3-7.5 (m, 10) ppm

Example 22

2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenylpropionitrile

7.3 g (28.8 mmol) of 2-hydroxy-3-methoxy-3,3-diphenylpropionitrile were dissolved in 90 ml of DMF, and 4 g (28.8 mmol) of K_2CO_3 and 6.3 g (28 mmol) of 2-methanesulfonyl-4,6-dimethoxypyrimidine were added. The mixture was stirred at room temperature for about 12 h, then poured into water and extracted with ethyl acetate. The combined organic phases were washed again with H_2O, dried and concentrated. The residue obtained in this way was then purified by chromatography on silica gel (n-hepane/ethyl acetate).

Yield: 6.9 g of white amorphous powder

FAB-MS: 392 (M+H$^+$) ^{1}H-NMR [$CDCl_3$], δ=3.3 (s, 3H); 4.95 (s, 6H), 5.85 (s, 1H); 6.3 (s, 1H); 7.3-7.5 (m, 10H) ppm

Example 23

5-[2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)propyl]-1H-tetrazole [[sic]]

0.5 g (1.3 mmol) of nitrile was dissolved in 10 ml of toluene, and 85 mg (1.3 mmol) of NaN_3 and 460 mg (1.4 mmol) of Bu_3SnCl were successively added, and then the mixture was refluxed for about 40 h. Cooling was followed by dilution with ethyl acetate and washing with 10% aqueous KF solution and with NaCl solution. After drying over $MgSO_4$ and concentration there remained 1.0 g of a yellow oil, which was purified by chromatography on silica gel (n-heptane/ethyl acetate).

Concentration of the fractions resulted in 60 mg of the 1H-tetrazole and 110 mg of the 1-methyltetrazole, each as amorphous white solids.

5-[2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)propyl]-1H-tetrazole [[sic]]

Electrospray-MS: 435 (M+H$^+$) ^{1}H-NMR ($CDCl_3$): δ (ppm) 3.28 (s, 3H), 3.85 (s, 6H), 5.75 (s, 1H), 7.25-7.40 (m, 10H), 7.50 (s, 1H).

5-[2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methoxy-3,3-diphenyl)propyl]-1-methyltetrazole [[sic]]

Electrospray-MS; 471 (M+H$^+$) ^{1}H-NMR ($CDCl_3$): δ (ppm) 3.0 (s, 3H), 3.35 (s, 3H[9]) [[sic]], 3.80 (s, 6H), 5.75 (s, 1H), 7.30-7.40 (m, 11H).

Example 24

2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methylsulfinyl-3,3-diphenylpropionic acid

1.2 g (2.9 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methylsulfonyl-3,3-diphenylpropionic [[sic]] acid were introduced into 15 ml of glacial acetic acid at 0° C. and 294 µl of 30% strength H_2O_2 were added dropwise. The mixture was stirred at room temperature overnight, poured into water, extracted with CH_2Cl_2 and washed with sodium thiosulfate solution and brine. After drying, 1 g of substance was isolated as a white foam.

Example 25

2-(4,6-Dimethoxy-2-pyrimidinyloxy)-3-methylsulfonyl-3,3-diphenylpropionic acid

0.6 g (1.45 mmol) of 2-(4,6-dimethoxy-2-pyrimidinyloxy)-3-methyl-sulfonyl-3,3-diphenylpropionic [[sic]] acid was introduced into 15 ml of glacial acetic acid at room temperature, and 294 µl of 30% strength H_2O_2 were added dropwise. The mixture was stirred at room temperature overnight, heated at 50° C. for a further 3 h, poured into water and washed with sodium thiosulfate solution and brine. After drying, 400 mg were isolated as a white solid.

The compounds listed in Table 1 [[sic]] can be prepared in a similar way.

TABLE 1



No.	R^1	R^4, R^5	R^6	R^2	R^3	X	Y	Z	m.p. [° C.]
[I-195]*I-1*	[OMe]OCH_3	Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	81
[I-196]*I-2*	OH	Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	167
[I-197]*I-3*	OH	Phenyl	CH_2—CH_2—S—CH_3	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-198]*I-4*	OH	Phenyl	Ethyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	81 (decomp.)
[I-199]*I-5*	OH	Phenyl	iso-Propyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	182
[I-200]*I-6*	OH	Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	S	168
[I-201]*I-7*	OH	Phenyl	CH_2—CH_2—SO_2—$CH(CH_3)_2$	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-202]*I-8*	OH	Phenyl	CH_2—CH_2—SO_2—$CH(CH_3)_2$	[OMe]OCH_3	[OMe]OCH_3	CH	S	O	
[I-203]*I-9*	OH	Phenyl	CH_2—CH_2—SO_2—$CH(CH_3)_2$	[OMe]OCH_3	[OMe]OCH_3	C—$CH(CH_3)_2$	O	O	
[I-204]*I-10*	OH	Phenyl	CH_2—CH_2—SO_2—$CH(CH_3)_2$	[OMe]OCH_3	[OMe]OCH_3	C—$CH(CH_3)_2$	O	O	
[I-205]*I-11*	OH	Phenyl	CH_2—CH_2—SO_2—$CH(CH_3)_2$	[OMe]OCH_3	NH•OCH_3	CH	O	O	
[I-206]*I-12*	OH	Phenyl	n-Propyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	174
[I-207]*I-13*	[OMe]OCH_3	Phenyl	n-Propyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-208]*I-14*	OH	Phenyl	n-Propyl	[OEt]OC_2H_5	[OEt]OC_2H_5	CH	O	O	
[I-209]*I-15*	OH	Phenyl	n-Butyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-210]*I-16*	OH	Phenyl	iso-Butyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-211]*I-17*	OH	Phenyl	iso-Butyl	[OMe]OCH_3	O—CH_2—CH_2—C		O	O	
[I-212]*I-18*	OH	Phenyl	tert.-Butyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-213]*I-19*	OH	Phenyl	Cyclopropyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-214]*I-20*	OH	Phenyl	Cyclopentyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-215]*I-21*	OH	Phenyl	Cyclohexyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-216]*I-22*	OH	Phenyl	$(CH_3)_3C$—CH_2—CH_2	[OEt]OC_2H_5	[OEt]OC_2H_5	CH	O	O	
[I-217]*I-23*	OH	Phenyl	$(CH_3)_2CH$—CH_2—CH_2—CH_2	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	173
[I-218]*I-24*	OH	Phenyl	HO—CH_2—CH_2	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-219]*I-25*	OH	Phenyl	HO_2C—$(CH_2)_2$—	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-220]*I-26*	OH	Phenyl	Cyclopropyl-methylene [[sic]]	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	115
[I-221]*I-27*	OH	Phenyl	H	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-222]*I-28*	OH	Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	—	
[I-223]*I-29*	OH	Phenyl	Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	136
[I-224]*I-30*	OH	Phenyl	Phenyl	[OMe]OCH_3	O—$CH(CH_3)$—CH_2—C		O	O	
[I-225]*I-31*	OH	Phenyl	Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-226]*I-32*	OH	Phenyl	4-Isopropyl-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-227]*I-33*	OH	Phenyl	4-Me*thyl*-S-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-228]*I-34*	OH	Phenyl	4-M*ethyl*-O-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-229]*I-35*	OH	Phenyl	3-E*thyl*-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-230]*I-36*	OH	Phenyl	2-M*ethyl*-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-231]*I-37*	OH	Phenyl	2-Cl-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-232]*I-38*	OH	Phenyl	3-Br-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-233]*I-39*	OH	Phenyl	4-F-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-234]*I-40*	OH	Phenyl	4-F-Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	S	O	
[I-235]*I-41*	OH	Phenyl	4-CH_3—Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-236]*I-42*	OH	Phenyl	3-NO_2—Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-237]*I-43*	OH	Phenyl	2-HO—Phenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-238]*I-44*	OH	Phenyl	3,4-Dimethoxyphenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-239]*I-45*	OH	Phenyl	3,4-Dioxomethylene-phenyl-[[sic]]	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	

TABLE 1-continued



No.	R^1	R^4, R^5	R^6	R^2	R^3	X	Y	Z	m.p. [° C.]
[I-240]*I-46*	OH	Phenyl	3,4,5-Triimethoxyphenyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-241]*I-47*	OH	Phenyl	Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-242]*I-48*	OH	Phenyl	2-Cl—Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-243]*I-49*	OH	Phenyl	3-Br—Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-244]*I-50*	OH	Phenyl	4-F—Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-245]*I-51*	OH	Phenyl	2-Me*thyl*-Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-246]*I-52*	OH	Phenyl	2-Me*thyl*-Benzyl	[OMe]OCH_3	O—CH═CH—C		O	O	
[I-247]*I-53*	OH	Phenyl	3-Et*hyl*-Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-248]*I-54*	OH	Phenyl	4-iso-Propyl-Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-249]*I-55*	OH	Phenyl	4-NO_2—Propyl-Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-250]*I-56*	OH	Phenyl	2-Me*thyl*-5-Propyl-Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-251]*I-57*	OH	Phenyl	2-Me*thyl*-5-Propyl-Benzyl	[OEt]OC_2H_5	[OEt]OC_2H_5	CH	O	O	
[I-252]*I-58*	OH	Phenyl	4-Me*thyl*-2-Propyl-Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-253]*I-59*	OH	Phenyl	3,4-Dioxomethyl-enebenzyl [[sic]]	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-254]*I-60*	OH	4-F—Phenyl	4-Me*thyl*-2-Propyl-Benzyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	163-165 (decomp.)
[I-255]*I-61*	[OMe]OCH_3	4-F—Phenyl	Methyl	[OEt]OC_2H_5	[OEt]OC_2H_5	CH	O	O	
[I-256]*I-62*	OH	4-Cl—Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-257]*I-63*	OH	4-Me*thyl*—O—Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-258]*I-64*	OH	4-Me*thyl*—O—Phenyl	Ethyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-259]*I-65*	OH	4-Me*thyl*-Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-260]*I-66*	OH	4-Me*thyl*-Phenyl	Methyl	[OMe]OCH_3	O—CH_2—CH_2—C		O	O	
[I-261]*I-67*	OH	3-CF_3—Phenyl	n-Propyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-262]*I-68*	OH	3-CF_3—Phenyl	n-Propyl	[OMe]OCH_3	O—CH(CH_3)—CH_2—C		O	O	
[I-263]*I-69*	OH	4-NO_2—Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-264]*I-70*	OH	4-NO_2—Phenyl	Methyl	[OMe]OCH_3	O—CH═CH—C		O	O	
[I-265]*I-71*	OH	3-Cl—Phenyl	Ethyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-266]*I-72*	OH	2-F—Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	193-194 (decomp.)
[I-267]*I-73*	OH	2-F—Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	S	O	
[I-268]*I-74*	OH	2-Me*thyl*—O—Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-269]*I-75*	OH	2-Me*thyl*—O—Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	S	
[I-270]*I-76*	OH	3,4-Dimethoxyphenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-271]*I-77*	OH	3,4-Dioxmethyl-enephenyl [[sic]]	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-272]*I-78*	OH	p-CF_3—Phenyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-273]*I-79*	OH	Phenyl	Methyl	[OMe]OCH_3	[OEt]OC_2H_5	CH	O	O	
[I-274]*I-80*	[OMe]OCH_3	Phenyl	Methyl	[OMe]OCH_3	[OEt]OC_2H_5	CH	O	O	
[I-275]*I-81*	OH	Phenyl	Ethyl	[OMe]OCH_3	NH—[OMe]OCH_3	CH	O	O	
[I-276]*I-82*	OH	p-Me*thyl*-O—Phenyl	n-Propyl	[OMe]OCH_3	OCF_3	CH	O	O	
[I-277]*I-83*	OH	Phenyl	Methyl	[OMe]OCH_3	CF_3	CH	O	O	
[I-278]*I-84*	OH	Phenyl	Methyl	[OMe]OCH_3	CF_3	N	O	O	
[I-279]*I-85*	OH	3,4-Dimethoxyphenyl	Benzyl	Me*thyl*	Me*thyl*		O	O	
[I-280]*I-86*	OH	3,4-Dimethoxyphenyl	Methyl	[OMe]OCH_3	O—CH_2CH_2—C		O	O	
[I-281]*I-87*	OH	Phenyl	Methyl	[OMe]OCH_3	O—CH_2—CH_2—C		O	O	126 (decomp.)
[I-282]*I-88*	OH	Phenyl	Methyl	[OMe]OCH_3	O—CH(CH_3)—CH_2—C		O	O	
[I-283]*I-89*	OH	Phenyl	Methyl	[OMe]OCH_3	N(CH_3)—CH═CH—C		O	O	118
[I-284]*I-90*	OH	Phenyl	Methyl	[OMe]OCH_3	S—C(CH_3)═C(CH_3)—C		O	O	
[I-285]*I-91*	OH	Phenyl	Methyl	[OMe]OCH_3	O—C(CH_3)═CH—C		O	O	
[I-286]*I-92*	OH	Phenyl	Methyl	Me*thyl*	O—C(CH_3)═CH—C		O	O	
[I-287]*I-93*	OH	Phenyl	Methyl	Me*thyl*	O—CH═CH—C		O	O	
[I-288]*I-94*	OH	4-F—Phenyl	Methyl	Me*thyl*	S—CH═CH—C		O	O	
[I-289]*I-95*	OH	4-F—Phenyl	H	[OMe]OCH_3	[OMe]OCH_3	CH	O	S	
[I-290]*I-96*	OH	Phenyl	Methyl	[OMe]OCH_3	CH_2—CH_2—CH_2—C		O	O	149-151 (decomp.)
[I-291]*I-97*	OH	Phenyl	Methyl	Methyl	CH_2—CH_2—CH_2—C		O	O	157 (decomp.)
[I-292]*I-98*	OH	Phenyl	Methyl	Ethyl	CH_2—CH_2—CH_2—CH_2—C		O	O	

TABLE 1-continued



No.	R^1	R^4, R^5	R^6	R^2	R^3	X	Y	Z	m.p. [° C.]
[I-293]*I-99*	OH	Phenyl	Methyl	[OMe]OCH_3	CH_2—CH_2—CH_2—CH_2—C		O	O	
[I-294]*I-100*	OH	Phenyl	Methyl	Methyl	Methyl	CH	O	O	
[I-295]*I-101*	OH	Phenyl	Methyl	Ethyl	Ethyl	CH	O	O	
[I-296]*I-102*	OH	Phenyl	Methyl	Methyl	Methyl	C—CH_3	O	O	
[I-297]*I-103*	OH	Phenyl	Methyl	[OMe]OCH_3	[Me]CH_3	CH	O	O	
[I-298]*I-104*	OH	Cyclohexyl	Methyl	[OMe]OCH_3	[OMe]OCH_3	CH	O	O	
[I-299]*I-105*	OH	Cyclohexyl	Methyl	[OMe]OCH_3	CH_2—CH_2—CH_2—C		O	O	
[I-300]*I-106*	OH	Phenyl	Methyl	OCH_3	OCH_3	CH	S	S	
[I-301]*I-107*	OH	Phenyl	Methyl	OCH_3	OCH_3	CH	O	S	134
[I-302]*I-108*	OCH_3	Phenyl	Methyl	OCH_3	OCH_3	CH	S	S	
[I-303]*I-109*	OH	Phenyl	Methyl	OCH_3	OCH_3	CH	O	O	
[I-304]*I-110*	OCH_3	2-Fluorophenyl	Methyl	OCH_3	OCH_3	CH	O	O	
[I-305]*I-111*	OC_2H_5	3-Chlorophenyl	Methyl	OCH_3	OCH_3	N	O	O	
[I-306]*I-112*	$ON(CH_3)_2$	4-Bromophenyl	Methyl	CF_3	CF_3	CH	S	O	
[I-307]*I-113*	O—CH_2—C═CH	Phenyl	Ethyl	OCH_3	CF_3	CH	O	O	
[I-308]*I-114*	OH	Phenyl	Propyl	OCH_3	OCF_3	CH	O	S	
[I-309]*I-115*	OCH_3	Phenyl	i-Propyl	OCH_3	CH_3	CH	O	O	
[I-310]*I-116*	OC_2H_5	Phenyl	s-Butyl	OCH_3	Cl	CH	S	O	
[I-311]*I-117*	$ON(CH_3)_2$	2-Methylphenyl	Methyl	OCH_3	OCH_3	CH	O	O	
[I-312]*I-118*	$ON(CH_3)_2$	3-Methoxyphenyl	Methyl	OCH_3	OCH_3	CH	O	O	
[I-313]*I-119*	$ON{=}C(CH_3)_2$	4-Nitrophenyl	Methyl	OCH_3	OCH_3	CH	O	O	
[I-314]*I-120*	$ON(CH_3)_2$	Phenyl	1-Phenylpropyn-3-yl	OCH_3	OCF_3	N	O	S	
[I-315]*I-121*	$ON{=}C(CH_3)_2$	2-Hydroxyphenyl	Methyl	OCH_3	CH_3	N	O	O	
[I-316]*I-122*	$ONSO_2(C_6H_5$	3-Trifluoromethyl-phenyl	Methyl	OCH_3	Cl	N	O	O	
[I-317]*I-123*	NH[Phenyl]—*phenyl*	4-Dimethyl-aminophenyl	Methyl	OCH_3	OCH_3	CH	S	O	
[I-318]*I-124*	OC_2H_5	Phenyl	Trifluoromethyl	CH_3	CH_3	CH	O	O	
[I-319]*I-125*	$ON(CH_3)_2$	Phenyl	Benzyl	Cl	Cl	CH	O	O	
[I-320]*I-126*	$ON(CH_3)_2$	Phenyl	2-Methoxyethyl	OCH_3	—O—CH_2—CH_2—		S	O	
[I-321]*I-127*	OH	Phenyl	Phenyl	OCH_3	OCH_3	CH	O	O	
[I-322]*I-128*	OH	Phenyl	Phenyl	OCH_3	—O—CH_2—CH_2—		O	O	
[I-323]*I-129*	OH	Phenyl	Phenyl	OCH_3	OCH_3	N	O	O	
[I-324]*I-130*	OH	Phenyl	Phenyl	OCH_3	OCH_3	CH	S	O	
[I-325]*I-131*	OH	Phenyl	Phenyl	OCH_3	OCH_3	CH	S	S	
[I-326]*I-132*	OH	Phenyl	Phenyl	OCH_3	OCH_3	CH	O	S	
[I-327]*I-133*	OH	Phenyl	Phenyl	OCH_3	OCH_3	CH	O	O	
[I-328]*I-134*	OH	Phenyl	Phenyl	OCH_3	OCH_3	CH	O	O	
[I-329]*I-135*	OH	—$(CH_2)_5$—	Phenyl	Phenyl	OCH_3	CH	O	O	
[I-330]*I-136*	OH	Phenyl	[2-thiozolyl]*2-thiazolyl*	OCH_3	OCH_3	CH	O	O	
[I-331]*I-137*	OCH_3	2-Fluorophenyl	Phenyl	OCH_3	OCH_3	CH	O	O	
[I-332]*I-138*	OC_2H_5	3-Chlorophenyl	Phenyl	OCH_3	OCH_3	N	O	O	
[I-333]*I-139*	$ON(CH_3)_2$	4-Bromophenyl	Phenyl	CF_3	CF_3	CH	O	O	
[I-334]*I-140*	[OCH2CH]*OCH2═CH*	Phenyl	2-Fluorophenyl	OCH_3	CF_3	CH	O	O	
[I-335]*I-141*	OH	Phenyl	3-Chlorophenyl	OCH_3	OCF_3	CH	O	S	
[I-336]*I-142*	OCH_3	Phenyl	4-Bromophenyl	OCH_3	CH_3	CH	O	O	
[I-337]*I-143*	OC_2H_5	Phenyl	4-Thiazolyl	OCH_3	Cl	CH	S	O	
[I-338]*I-144*	$ON(CH_3)_2$	2-Methylphenyl	Phenyl	OCH_3	OCH_3	CH	O	O	
[I-339]*I-145*	$ON{=}C(CH_3)_2$	2-Methoxyphenyl	Phenyl	OCH_3	OCH_3	CH	O	O	
[I-340]*I-146*	OH	Phenyl	Methyl	OCH_3	—CH_2—CH_2—CH_2—C		O	O	
[I-341]*I-147*	OH	4-Fluorophenyl	Methyl	OCH_3	OCH_3	CH	O	O	168 (decomp.)
[I-342]*I-148*	OH	4-Fluorophenyl	Methyl	OCH_3	—CH_2—CH_2—CH_2—C		O	O	
[I-343]*I-149*	NH—SO—C_6H_5	4-Nitrophenyl	Phenyl	OCH_3	OCH_3	CH	O	O	
[I-344]*I-150*	OCH_3	Phenyl	3-Imidazolyl	OCH_3	—O—CH_2—CH_2		O	O	
[I-345]*I-151*	OC_2H_5	Phenyl	4-Imidazolyl	OCH_3	CF_3	N	S	O	
[I-346]*I-152*	$ON(CH_3)_2$	Phenyl	2-Pyrazolyl	OCH_3	OCF_3	N	O	S	
[I-347]*I-153*	$ON{=}C(CH_3)_2$	2-Hydroxyphenyl	Phenyl	OCH_3	CH_3	N	O	O	
[I-348]*I-154*	NH—SO_2—C_6H_5	3-Trifluoromethyl-phenyl	Phenyl	OCH_3	Cl	N	O	O	
[I-349]*I-155*	NH[Phenyl]—*phenyl*	4-Dimethylamino-phenyl	Phenyl	OCH_3	OCH_3	CH	S	O	
[I-350]*I-156*	ONa	Phenyl	Phenyl	OCH_3	OCH_3	CH	S	S	

TABLE 1-continued



No.	R^1	R^4, R^5	R^6	R^2	R^3	X	Y	Z	m.p. [° C.]
[I-351]*I-157*	O—CH_2—C≡C	Phenyl	Phenyl	OCH_3	OCH_3	N	S	S	
[I-352]*I-158*	OH	Phenyl	Phenyl	CF_3	CF_3	CH	O	S	
[I-353]*I-159*	OCH_3	Phenyl	Phenyl	OCF_3	OCF_3	CH	O	O	
[I-354]*I-160*	OC_2H_5	Phenyl	2-Dimethylamino-phenyl	CH_3	CH_3	CH	O	O	
[I-355]*I-161*	ONC$(CH_3)_2$	Phenyl	3-Hydroxyphenyl	Cl	Cl	CH	O	O	
[I-356]*I-162*	ON═C$(CH_3)_2$	Phenyl	4-Trifluoromethyl-phenyl	OCH_3	—O—CH_2—CH_2—		S	O	
[I-357]*I-163*	NH—SO_2—C_6H_5	Phenyl	2-Oxazolyl	OCH_3	CF_3	N	S	S	
[I-358]*I-164*	OH	Phenyl	Methyl	CH_3	CH_3	CH	O	O	
[I-359]*I-165*	OH	Cyclohexyl	Methyl	OCH_3	OCH_3	CH	O	O	
[I-360]*I-166*	OH	Cyclohexyl	Methyl	OCH_3	CH_2—CH_2—CH—C		O	O	
[I-361]*I-167*	OH	Phenyl	Methyl	$N(CH_3)_2$	$N(CH_3)_2$	CH	O	O	
[I-362]*I-168*	OH	Phenyl	Methyl	OCH_3	OCH_3	CH	O	SO_2	
[I-363]*I-169*	OH	Phenyl	Methyl	OCH_3	OCH_3	CH	O	SO_2	
[I-364]*I-170*	OH	3-F—Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-365]*I-171*	OH	3-F—Phenyl	*Methyl*	[OMe]*OCH_3*	CH_2—CH_2—CH_2—C		O	O	
[I-366]*I-172*	OH	4-F—Phenyl	*Methyl*	[OMe]*OCH_3*	CH_2—CH_2CH_2—C		O	O	142-143 191° C.
[I-367]*I-173*	OH	3-*Methyl*—O—Phenyl	*Methyl*	[OMe]*OCH_3*	CH_2—CH_2—CH_2—C		O	O	158-161 (decomp.)
[I-368]*I-174*	OH	3-*Methyl*—O—Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-369]*I-175*	OH	3-*Methyl*—O—Phenyl	*Ethyl*	[OMe]*OCH_3*	CH_2—CH_2—CH_2—C		O	O	
[I-370]*I-176*	OH	Phenyl	HO—CH_2—CH_2	[OMe]*OCH_3*	CH_2—CH_2—CH_2—C		O	O	
[I-371]*I-177*	OH	Phenyl	*Methyl*	[NMe_2] *$N(CH_3)_2$*	[NMe_2] *$N(CH_3)_2$*	N	O	O	181
[I-372]*I-178*	OH	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	N	O	O	
[I-323]*I-179*	OH	*3-F—Phenyl*	*Methyl*	*OCH_3*	*CH_3*	*CH*	*O*	*O*	
[I-374]*I-180*	NH—SO_2—Phenyl	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-375]*I-181*	NH—SO_2—[Me] *CH_3*	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-376]*I-182*	CH_2—SO_2—Phenyl	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-377]*I-183*	NH—SO_2—[Me] *CH_3*	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-378]*I-184*	—CN	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-379]*I-185*	Tetrazole[[sic]]	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-380]*I-186*	NH—SO_2—Phenyl	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	167
[I-381]*I-187*	N—Methyltetra-zole[[sic]]	Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	
[I-382]*I-188*	ONa	Phenyl	*Methyl*	[OMe]*OCH_3*	—O—CH_2—CH_2—C—		O	O	122-139 (*decomp.*) [(zers.)]
[I-383]*I-189*	OH	o-F—Phenyl	*Methyl*	[OMe]*OCH_3*	—O—CH_2—CH_2—C—		O	O	140-144 (decomp.)
[I-384]*I-190*	OH	m-*Methyl*-Phenyl	*Methyl*	[OMe]*OCH_3*	[OMe]*OCH_3*	CH	O	O	169-177
[I-385]*I-191*	OH	m-*Methyl*-Phenyl	*Methyl*	[OMe]*OCH_3*	—O—CH_2—CH_2—C—		O	O	119-135 (decomp.)
[I-386]*I-192*	OH	p-F—Phenyl	*Methyl*	[OMe]*OCH_3*	[Me]*CH_3*	CH	O	O	137-140 (decomp.)
[I-387]*I-193*	OH	m-F—Phenyl	*Methyl*	*Methyl*	—O—CH_2—CH_2—C—		O	O	150-152
[I-388]*I-194*	OH	p-F—Phenyl	*Methyl*	*Methyl*	—O—CH_2—CH_2—C—		O	O	169-170

TABLE 11



No.	R^1	A	R^6	R^2	R^3	X	Y	Z	m.p. [° C.]
II-1	OH	Bond	Methyl	OMe*thyl*	OMe*thyl*	CH	O	O	96-98
II-2	OH	CH_2	Methyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-3	OH	CH_2—CH_2	Methyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-4	OH	CH═CH	Methyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-5	OH	O	Methyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-6	OH	S	Methyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-7	OH	$NH(CH_3)$	Methyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-8	OH	Bond	Isopropyl	OMe*thyl*	OMe*thyl*	CH	O	O	137-139
II-9	OH	Bond	p-Isopropylphenyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-10	OH	Bond	Benzyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-11	OH	CH═CH	Ethyl	OMe*thyl*	OMe*thyl*	CH	O	O	
II-12	OH	CH═CH	$(CH_3)_2$—CH_2—CH_2	OMe*thyl*	OMe*thyl*	CH	O	O	
II-13	OH	CH═CH	Cyclopropylmethyl [ene][[sic]]	OMe*thyl*	OMe*thyl*	CH	O	O	
II-14	OH	CH═CH	Methyl	OMe*thyl*	O—CH_2—CH_2—C	O	O		
II-15	OH	CH_2—CH_2	Ethyl	OMe*thyl*	O—CH═CH—C	O	O		
II-16	OH	[CH_2═CH_2] *CH_2—CH_2*	Methyl	OMe*thyl*	CH_2—CH_2—CH_2—C	O	O		
II-17	OH	Bond	Methyl	OMe*thyl*	CH_2—CH_2—CH_2—C	O	O		147

Example 35

Receptor binding data were measured by the binding assay described above for the compounds listed below. The results are shown in Table 2 [[sic]].

TABLE 2

Receptor binding data (K_i values)

Compound	ET_A [nM]	ET_B [nM]
I-2	6	34
I-29	86	180
I-5	12	160
I-4	7	2500
I-87	1	57
I.89	86	9300
I-103	0.4	29
I-107	3	485
I-12	19	1700
I-26	23	2000
I-23	209	1100
I-47	150	1500
I-60	33	970
I-96	0.6	56
II-3	107	7300
II-1	28	2300

We claim:

1. A compound of the formula I



(I)

where

R is formyl, tetrazole, nitrile, [a COOH group] —CO_2H or a radical which can be hydrolyzed to [COOH, and the other substituents have the following meanings:] —CO_2H;

R^2 *is* hydrogen, hydroxyl, —NH_2, —$NH(C_1$-C_4-alkyl), —$N(C_1$-C_4-alkyl$)_2$, halogen, C_1-C_4-alkyl, *or* C_1-C_4-haloalkyl[, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy or C_1-C_4-alkylthio];

X is CR^{14}, *where* R^{14} *is hydrogen or* C_1-C_5-*alkyl;*

R^3 *is* hydrogen, hydroxyl, —NH_2, —$NH(C_1$-C_4-alkyl), —$N(C_1$-C_4-alkyl$)_2$, halogen, C_1-C_4-alkyl, *or* C_1-C_4-haloalkyl[, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, NH—O—C_1-C_4-alkyl, C_1-C_4-alkylthio or CR^3 is linked to CR^{14} as indicated above to give a 5- or 6-membered ring];

R^4 and R^5, which can be identical or different, are phenyl or naphthyl, which can be substituted by one or more of the

following [radicals] *selected from the group consisting of*: halogen, nitro, cyano, hydroxyl, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, phenoxy, C_1-C_4-alkylthio, amino, C_1-C_4-alkylamino [or] *and* C_1-C_4-dialkylamino; or *R^4 and R^5 are*

phenyl or naphthyl, which are connected together in the ortho position via a direct linkage, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom [or], an SO_2, NH or N-alkyl group[;] or *a* C_3-C_7-cycloalkyl *group*;

R^6 *is* hydrogen, *or R^6 is* C_1-C_8-alkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl or C_3-C_8-cycloalkyl, where each of these [radicals] can be substituted *by* one or more [times by] *substituents selected from the group consisting of*: halogen, nitro, cyano, C_1-C_4-alkoxy, C_3-C_6-alkenyloxy, C_3-C_6-alkynyloxy, C_1-C_4-alkylthio, C_1-C_4-haloalkoxy, C_1-C_4-alkylcarbonyl, C_1-C_4-alkoxycarbonyl, C_3-C_8-alkylcarbonylalkyl, C_1-C_4-alkylamino, di-C_1-C_4-alkylamino, phenyl [or] *and* phenoxy which *phenyl or phenoxy* is substituted *by* one or more [times by] *substituents selected from the group consisting of:* halogen, nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy [or] *and* C_1-C_4-alkylthio; *or*

phenyl or naphthyl, each of which can be substituted by one or more of the following [radicals] *selected from the group consisting of*: halogen, nitro, cyano, hydroxyl, amino, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, phenoxy, C_1-C_4-alkylthio, C_1-C_4-alkylamino, C_1-C_4-dialkylamino , dioxomethylene [or] *and* dioxoethylene; *or*

a five or six-membered heteroaromatic moiety containing (*i*) one to three nitrogen atoms, [and/or one sulfur or oxygen atom] (*ii*) *one sulfur atom,* (*iii*) *one oxygen atom,* (*iv*) *one to three nitrogen atoms and one sulfur atom, or* (*v*) *one to three nitrogen atoms and one oxygen atom*, which *heteroaromatic moiety* can carry *one or more substituents selected from the group consisting of:* one to four halogen atoms [and/or], *and* one or two of the following [radicals] *selected from the group consisting of*: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, C_1-C_4-alkylthio, phenyl, phenoxy [or] *and* phenylcarbonyl, it being possible for the phenyl [radicals] in turn to carry *one or more substituents selected from the group consisting of:* one to five halogen atoms [and/or], *and* one to three of the following [radicals] *selected from the group consisting of*:

C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and[/or] C_1-C_4-alkylthio[;],

Y *is* sulfur [or], oxygen or a single bond; *and*

Z *is* sulfur, oxygen, —SO— or —SO_2—.

2. The compound of the formula I as defined in claim **1**, wherein X is CR^{14} and R^{14} is hydrogen.

3. The compound of the formula I as defined in claim **2**, wherein R is CO_2H.

[**4**. The compound of the formula I as defined in claim **2**, wherein R^2 and R^3 each is methoxy.]

5. The compound of the formula I as defined in claim **2**, wherein R^4 and R^5 each is phenyl.

6. The compound of the formula I as defined in claim **2**, wherein R^6 is C_1-C_8-alkyl.

7. The compound of the formula I as defined in claim **2**, wherein Y is oxygen.

8. The compound of the formula I as defined in claim **2**, wherein Z is oxygen or sulfur.

9. The compound of the formula I as defined in claim **8**, wherein Z is oxygen.

[**10**. The compound of the formula I as defined in claim **1**, wherein

X is CH,

Y is oxygen,

Z is oxygen,

R is CO_2H,

R^2 is methoxy,

R^3 is methoxy,

R^4 is phenyl,

R^5 is phenyl,

R^6 is methyl, ethyl or iso-propyl.]

11. The compound of the formula I as defined in claim **1**, wherein R is tetrazole, nitrile or a group

where R^1 has the following meanings:

a) hydrogen;

b) succinylimidoxy;

c) a five-membered heteroaromatic ring linked by a nitrogen atom, selected from the group consisting of: pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which ring can carry *one or more substituents selected from the group consisting of*: one or two halogen atoms [and or], *and* one or two of the following [radicals] *selected from the group consisting of*: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy [or] *and* C_1-C_4-alkylthio;

d) a radical



where m is 0 or 1 and R^7 and R^8, which can be identical or different, have the following meanings:

hydrogen,

C_1-C_8-alkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl, C_3-C_8-cycloalkyl, where these alkyl, cycloalkyl, alkenyl and alkynyl groups can each carry *one or more substituents selected from the group consisting of:* one to five halogen atoms [and/or], *and* one or two of the following groups *selected from the group consisting of*: C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkylthio, C_1-C_4-haloalkoxy, C_3-C_6-alkenyloxy, C_3-C_6-alkenylthio, C_3-C_6-alkynyloxy [or] C_3-C_6-alkynylthio, C_1-C_4-alkylcarbonyl, C_1-C_4-alkoxycarbonyl, C_3-C_6-alkenylcarbonyl, C_3-C_6-alkynylcarbonyl, C_3-C_6-alkenyloxycarbonyl [or] *and* C_3-C_6-alkynyloxycarbonyl[,];

phenyl, which can be substituted *by* one or more [times by] *substituents selected from the group consisting of:* halogen, nitro, cyano, C_3-C_6-alkenylcarbonyl, C_3-C_6-alkynylcarbonyl, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy [or], C_1-C_4-alkylthio, *and* di-C_1-C_4-alkylamino, or

R^7 and R^8 together form a C_4-C_7-alkylene chain which can be substituted by C_1-C_4-alkyl, and may contain a hetero atom selected from the group consisting of: oxygen, sulfur and nitrogen, or R^7 and R^8 together form a CH_2—CH═CH—CH_2 or CH═CH—$(CH_2)_3$ chain;

e) a radical



where k is 0, 1 and 2, p is 1, 2, 3 and 4, and R^9 is C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl or phenyl, which can be substituted *by* one or more [times by] *substituents selected from the group consisting of:* halogen, nitro, cyano, C_3-C_6-alkenylcarbonyl, C_3-C_6-alkynylcarbonyl, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy [or] *and* C_1-C_4-alkylthio;

f) a radical OR^{10}, where R^{10} is

hydrogen, the cation of an alkali metal or an alkaline earth metal or an environmentally compatible organic ammonium ion;

C_3-C_8-cycloalkyl which may carry one to three C_1-C_4-alkyl groups;

C_1-C_8-alkyl which may carry *one or more substituents selected from the group consisting of:* one to five halogen atoms [and/or], *and* one of the following [radicals] *selected from the group consisting of*: C_1-C_4-alkoxy, C_1-C_4-alkylthio, cyano, C_1-C_4-alkylcarbonyl, C_3-C_8-cycloalkyl, C_1-C_4-alkoxycarbonyl, phenyl, phenoxy [or] *and* phenylcarbonyl, where the aromatic [radicals] *substituents* in turn may carry *one or more substituents selected from the group consisting of:* one to five halogen atoms [and/or], *and* one to three of the following [radicals] *selected from the group consisting of*: nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and[/or] C_1-C_4-alkylthio;

C_1-C_8-alkyl which may carry one to five halogen atoms and which carries one of the following [radicals] *selected from the group consisting of*: a 5-membered heteroaromatic ring containing one to three nitrogen atoms [or], a nitrogen atom and an oxygen [or] *and a nitrogen atom and a* sulfur atom, which may carry *one or more substituents selected from the group consisting of:* one to four halogen atoms [and/or], *and* one or two of the following [radicals] *selected from the group consisting of*: nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, phenyl, C_1-C_4-haloalkoxy and[/or] C_1-C_4-alkylthio;

C_2-C_6-alkyl which carries one of the following [radicals] in position 2: C_1-C_4-alkoxyimino, C_3-C_6-alkynyloxyimino, C_3-C_6-haloalkenyloxyimino or benzyloxyimino;

C_3-C_6-alkenyl or C_3-C_6-alkynyl which may carry one to five halogen atoms;

phenyl which may carry *one or more substituents selected from the group consisting of:* one to five halogen atoms [and/or], *and* one to three of the following [radicals] *selected from the group consisting of*: nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and[/or] C_1-C_4-alkylthio;

a 5-membered heteroaromatic ring which is bonded via a nitrogen atom and containing one to three nitrogen atoms, which may carry *one or more substituents selected from the group consisting of:* one or two halogen atoms, and [or] one or two of the following [radicals] *selected from the group consisting of*: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, phenyl, C_1-C_4-haloalkoxy and[/or] C_1-C_4-alkylthio;

a radical



where [R^1] R^{11} and R^{12}, which may be identical or different are:

C_1-C8-alkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl, C_3-C_8-cycloalkyl, it being possible for these [radicals] to carry [a] *one or more substituents selected from the group consisting of:* C_1-C_4-alkoxy, C_1-C_4-alkylthio, and[/or] phenyl, which may carry *one or more substituents selected from the group consisting of:* one to five halogen atoms [and/or], *and* one to three of the following [radicals] *selected from the group consisting of*: nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy and[/or] C_1-C_4alkylthio;

phenyl which may carry one or more of the following [radicals] *selected from the group consisting of*: halogen, nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy [or] *and* C_1-C_4-alkylthio; or R^{11} and R^{12} together form a C_3-C_{12}-alkylene chain which may carry one to three C_1-C_4-alkyl groups and which may contain a hetero atom selected from the group consisting of*:* *a* nitrogen, oxygen and sulfur;

g) a radical



where R^{13} is

C_1-C_4-alkyl, C_3-C_6-alkenyl, C_3-C_6-alkynyl, C_3-C_8-cycloalkyl, it being possible for these [radicals] to carry *one or more substituents selected from the group consisting of:* a C_1-C_4-alkoxy, *a* C_1-C_4-alkylthio [and/or a phenyl radical,] *and a phenyl;* or

phenyl which may carry one or more of the following [radicals] *selected from the group consisting of*: halogen, nitro, cyano, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy [or] *and* C_1-C_4-alkylthio.

12. The compound of the formula I as defined in claim 1, wherein

R is —CO_2H or a radical which can be hydrolyzed to —CO_2H;

R^4 is phenyl; and

R^5 is phenyl.

13. The compound of the formula I as defined in claim 12, wherein

X is CH;

Y is oxygen;

Z is oxygen;

R is —CO_2H;

R^2 is C_1-C_4-alkyl;

R^3 is C_1-C_4-alkyl; and

R^6 is C_1-C_8-alkyl.

14. The compound of the formula I as defined in claim 13, wherein

R^2 is methyl; and

R^3 is methyl.

15. The compound of the formula as defined in claim 1, wherein

R is formyl, —CO_2H or a radical which can be hydrolyzed to —CO_2H;

R^2 is C_1-C_4-alkyl;

X is CR^{14}, where R^{14} is hydrogen or C_1-C_5-alkyl;

R^3 is C_1-C_4-alkyl;

R^4 and R^5 which can be identical or different, are phenyl, which can be substituted by one or more of the following selected from the group consisting of: halogen, nitro, hydroxyl, C_1-C_4-alkyl, C_1-C_4-alkoxy and C_1-C_4-alkylthio; or

phenyl which are connected together in the ortho positions by a direct linkage, methylene, ethylene, ethenylene, oxygen, sulfur, —SO_2—, —NH— or N-alkyl group; or

C_3-C_7-cycloalkyl;

R^6 is C_1-C_8-alkyl, C_3-C_6-alkenyl or C_3-C_8-cycloalkyl, where each of these can be substituted by one or more substituents selected from the group consisting of: halogen, hydroxyl, nitro, cyano, C_1-C_4-alkoxy, C_3-C_6-alkenyloxy and C_1-C_4-alkylthio; or

phenyl or naphthyl, each of which can be substituted by one or more of the following selected from the group consisting of: halogen, nitro, cyano, hydroxyl, amino, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-haloalkoxy, phenoxy, C_1-C_4-alkylthio, C_1-C_4-alkylamino and C_1-C_4-dialkylamino; or

a five- or six-membered heteroaromatic moiety containing (i) a nitrogen atom, (ii) a sulfur atom, (iii) an oxygen atom, (iv) a nitrogen atom and a sulfur atom, or (v) a nitrogen atom and an oxygen atom, which heteroaromatic moiety can carry one or more substituents selected from the group consisting of: one to four halogen atoms, and one or two of the following selected from the group consisting of: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-alkylthio, phenyl, phenoxy and phenylcarbonyl, it being possible for the phenyl in turn to carry one or more substituents selected from the group consisting of: one to five halogen atoms, and one to three of the following selected from the group consisting of: C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy and C_1-C_4-alkylthio;

Y is sulfur, oxygen or a single bond; and

Z is sulfur, oxygen, SO or SO_2.

16. The compound of the formula I as defined in claim 15, wherein

R is —CO_2H;

R^2 is C_1-C_4-alkyl;

X is CR^{14}, where R^{14} is hydrogen;

R^3 is C_1-C_4-alkyl;

R^4 and R^5 which can be identical or different, are phenyl, which can be substituted by one or more of the following selected from the group consisting of: halogen, nitro, hydroxyl, C_1-C_4-alkyl, C_1-C_4-alkoxy and C_1-C_4-alkylthio;

R^6 is C_1-C_8-alkyl, which can by substituted by one or more substituents selected from the group consisting of: halogen, hydroxyl, nitro, cyano, C_1-C_4-alkoxy, C_3-C_6-alkenyloxy and C_1-C_4-alkylthio;

Y is oxygen; and

Z is oxygen.

17. The compound of the formula I as defined in claim 16, where R^4 and R^5 are each phenyl.

18. The compound of the formula I as defined in claim 1, wherein

R is —CO_2H or a radical which can be hydrolyzed to —CO_2H;

R^2 is C_1-C_4-alkyl;

X is CR^{14}, where R^{14} is hydrogen;

R^3 is C_1-C_4-alkyl;

R^4 and R^5 which can be identical or different, are phenyl, which can be substituted by one or more of the following selected from the group consisting of: halogen, nitro, hydroxyl, C_1-C_4-alkyl, C_1-C_4-alkoxy and C_1-C_4-alkylthio;

R^6 is C_1-C_8-alkyl, which can be substituted by one or more substitutents selected from the group consisting of: halogen, hydroxyl, nitro, cyano, C_1-C_4-alkoxy, C_3-C_6-alkenyloxy and C_1-C_4-alkylthio;

Y is oxygen; and

Z is oxygen.

19. The compound of the formula I as defined in claim 18, where R^4 and R^5 are each phenyl.

20. The compound of the formula I as defined in claim 1, wherein

R is —CO_2H;

R^2 is C_1-C_4-alkyl;

X is CR^{14}, where R^{14} is hydrogen or C_1-C_5-alkyl;

R^3 is C_1-C_4-alkyl;

R^4 and R^5 are phenyl which can be substituted by one or more halogen atoms;

R^6 is C_1-C_8-alkyl or C_3-C_8-cycloalkyl, where each of these can be substituted one or more times by phenyl, or phenyl;

Y is oxygen; and

Z is sulfor or oxygen.

21. The compound of the formula I as defined in claim 1, wherein

R is —CO_2H or a radical which can be hydrolyzed to CO_2H;

R^2 is halogen, C_1-C_4-alkyl or C_1-C_4-haloalkyl;

X is CR^{14}, where R^{14} is hydrogen or C_1-C_5-alkyl;

R^3 is halogen, C_1-C_4-alkyl or C_1-C_4-haloalkyl;

R^4 and R^5 are phenyl, which can be substituted by one or more of the following selected from the group consisting of: halogen, nitro, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy, C_1-C_4-alkylamino and C_1-C_4-dialkylamino;

R^6 is hydrogen, or R^6 is C_1-C_8-alkyl or C_3-C_8-cycloalkyl, where each of these can be substituted by one or more substituents selected from the group consisting of: halogen, hydroxyl, C_1-C_4-alkoxy, C_1-C_4-alkylthio and phenyl which is substituted by one or more substituents selected from the group consisting of: halogen, C_1-C_4-alkyl, C_1-C_4-haloalkyl, C_1-C_4-alkoxy and C_1-C_4-alkylthio; or

phenyl which can be substituted by one or more of the following selected from the group consisting of: halogen, nitro, hydroxyl, C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkylthio and dioxomethylene; or

a five or six-membered heteroaromatic moiety containing (i) one to three nitrogen atoms, (ii) one sulfur atom, (iii) one oxygen atom, (iv) one to three nitrogen atoms and one sulfur atom, or (v) one to three nitrogen atoms and one oxygen atom which heteroaromatic moiety can carry one to four halogen atoms;

Y is sulfur or oxygen; and

Z is sulfur or oxygen.

22. The compound of claim 21, wherein

R is $—CO_2H$, $—COOCH_3$, $—COON(CH_3)_2$, $—COOCH_2C{\equiv}CH$, $—COOC_2H_5$, $—COON{=}C(CH_3)_2$, —COONH-phenyl, $—COOCH{=}CH_2$ or $—CONH—SO—C_6H_5$;

R^2 is —Cl, $—CH_3$, $—CH_2CH_3$ or $—CF_3$;

X is CR^{14}, where R^{14} is hydrogen;

R^3 is —Cl, $—CH_3$, $—CH_2CH_3$ or $—CF_3$;

R^4 and R^5 are phenyl, which can be substituted by one or more groups selected from the group consisting of: —F, —Cl, —Br, $—CH_3$, $—CH_2CH_3$, $—CF_3$, $—OCH_3$, $—NO_2$ and $—N(CH_3)_2$;

R^6 is —H, $—CH_3$, $—CH_2CH_3$, $—CH_2CH_2CH_3$, $—C(CH_3)_3$, $—CH_2CH(CH_3)_2$, cyclopropyl, $—CH_2CH_2CH_2CH(CH_3)_2$, $—CH_2—CH_2—S—CH_3$, $—CH_2CH_2OH$, phenyl, trifluoroethyl, p-isopropyl-phenyl, p-methyl-S-phenyl, p-methyl-O-phenyl, m-ethyl-phenyl, o-methyl-phenyl, o-Cl-phenyl, m-Br-phenyl, p-F-phenyl, p-methyl-phenyl, $m\text{-}NO_2$-phenyl, o-HO-phenyl, 3,4-dimethoxy-phenyl, 3,4-dioxomethylene-phenyl, 3,4,5-trimethoxy-phenyl, benzyl, o-Cl-benzyl, m-Br-benzyl, p-F-benzyl, o-methyl-benzyl, m-ethyl-benzyl or p-isopropyl-benzyl;

Y is sulfur or oxygen; and

Z is sulfur or oxygen.

23. The compound of claim 22, wherein R^4 and R^5 are each phenyl.

24. A compound of the formula I:



(I)

where

R is $—CO_2H$;

R^2 is C_1-C_4-alkyl;

X is CR^{14}, where R^{14} is hydrogen;

R^3 is C_1-C_4-alkyl;

R^4 and R^5 which can be identical or different, are phenyl, which can be substituted by one or more of the following selected from the group consisting of: halogen, nitro, hydroxyl, C_1-C_4-alkyl, C_1-C_4-alkoxy and C_1-C_4-alkylthio;

R^6 is a C_1-C_8-alkyl, which can be substituted by one or more substituents selected from the group consisting of: halogen, hydroxyl, nitro, cyano, C_1-C_4-alkoxy, C_3-C_6-alkenyloxy and C_1-C_4-alkylthio;

Y is oxygen; and

Z is oxygen.

25. The compound of the formula I as defined in claim 24, wherein R^4 and R^5 are each phenyl.

* * * * *